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Heart disease is the leading cause of death nationwide, killing one of every four Americans in all 
communities. The health care costs associated with heart disease have been estimated to surpass 
300 billion dollars in 2010. Various preventative risk factors have been identified like obesity, 
diabetes, cigarette smoking, and air pollution. Pulmonary hypertension (PH) is a common 
secondary pathogenesis associated with cardiovascular disease. Understanding its exact 
physiological mechanisms will allow for better treatment options and better ways of preventing 
the disease. 
The importance of nitric oxide (NO) in biology was recognized in 1998 when the Nobel 
Prize in Physiology or Medicine was awarded for its discovery as a physiologic signaling 
molecule and was validated again in 1992 by naming it “the molecule of the year”. NO, 
produced in the endothelium by the enzyme nitric oxide synthase (eNOS), is critical in 
maintaining blood pressure by functioning as vasodilator. Its lack in the vascular system leads to 
problems, like heart disease and PH. As a critical signaling molecule, NO is likely to be 
important in transducing the effects of a broad variety of environmental stimuli on vasomotor 
regulation and studying the regulation of NO‘s biosynthetic capacity is of great public health 
importance. 
Recent studies demonstrate that the glycoprotein thrombospondin-1 (TSP1) influences 
vascular responses by interfering with the NO-mediated vasodilatory pathway at downstream 
 iv 
targets. We hypothesized that TSP1 directly modulates eNOS activity and, thus, endothelium-
dependent relaxation of blood vessels. Further, we were interested in how the inhibitory effects 
of TSP1 on eNOS would translate in a disease setting, specifically PH.  This study demonstrates 
TSP1’s negative role in the protective NO-mediated vasodilatory pathway and establishes a clear 
role for TSP1 in the development of PH. Despite the advent of several new drugs for the 
treatment of PH mortality remains high. Importantly, these drugs aim at increasing NO’s 
bioavailability. The studies described herein suggest that increased TSP1 expression may limit 
the efficacy of these drugs.  A deeper understanding of the role of TSP1 in physiology and 
disease will open new avenues in our fight to prevent heart disease.  
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1.0  INTRODUCTION 
1.1 THROMBOSPONDIN OVERVIEW 
The thrombospondin family consists of five proteins, thrombospondin (I-V)1. All isoforms 
contain a common structural “signature piece”. While thrombospondin 1 (TSP1) and 
thrombospondin 2 (TPS2) are trimeric proteins, TSP3-5 are pentamers. Expression of TSP is 
tissue specific. TSP1 and TSP2 are both expressed by vascular cells, like smooth muscle and 
endothelial cells, but only TSP1 is expressed by the α-granules of platelets. Upon hemostasis and 
thrombin-induced platelet aggregation 2-3  TSP1 is released from platelets and constitutes the 
main source of soluble TSP in the blood. This thesis will only focus on TSP1. TSP3, 4, and 5 are 
expressed in bone and cartilage and, though having some homology with TSP1, their role in 
modulating cardiovascular events has not been yet defined. 
TSP1, an adhesive glycoprotein, was first identified in 1971 by Nancy Baenziger. 
Exposure of intact platelets to thrombin led their group to observe the appearance of a large 
protein that they called “Thrombin-sensitive protein” 4 now called thrombospondin 1.  
1.1.1 Structure of Thrombospondin 
TSP1 is a 450 kDa trimeric glycoprotein composed of three identical 145 kDa polypeptide chains 
linked by disulfide bonds. Various structural domains have been identified on each monomer 5: 
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1. a NH2-terminal globular domain of the laminin G domain and concanavalin A-like 
lectin/glucanase superfamily; 2. an α-helical region that has been suggested to form a parallel 
homotrimeric coiled coil; 3. a von Willebrand factor type C module; and 4. three TSP type 1 
repeats that are homologous to the globulin protein properdin and a malarial coat protein. Each 
repeat consists of a novel, antiparallel three-stranded fold. The monomer is further composed of 
a “signature” piece that encompasses three epidermal growth factor (EGF)–like TSP type 2 
repeats and seven calcium- binding type 3 repeats. The last calcium binding repeat contains an 
arginine-glycine-aspartic acid (RGD) sequence. The COOH-terminal domain forms a lectin-like 
β-sandwich 1. 
The overall three-dimensional structure is further determined by interactions of the 
“signature piece” which forms three structural regions termed the stalk, wire and globe. These 
are additionally stabilized by disulfide bonds and bound calcium 6-7. 
1.1.2 Thrombospondin Signaling 
Expression of TSP1 is widespread and in addition to its expression in platelets and 
megakaryocytes 8, TSP1 has been reported to be produced by endothelial cells 9-10, smooth 
muscle cells, glial cells, type II pneumocytes, fibroblasts, keratinocytes and macrophages 11. 
Thrombospondin is abundantly expressed following injury in the extracellular matrix and can 
interact with fibronectin, heparin sulfate proteoglycans, heparin, collagen, laminin, as well as 
with plasma proteins like fibrinogen, plasminogen, and histidine rich glycoproteins 11. In the 
absence of disease TSP1 occurs in only two locations in the vascular system – as a soluble 
protein in the blood and preformed in the alpha granules of platelets. 
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In the last several years it was shown that activation of CD47 by TSP1 leads to decreased 
production of cGMP in endothelial and smooth muscle cells and in platelets, followed by 
changes in vascular responses like blood flow and tissue survival 12-19. These responses to TSP1 
have been shown to be due to its interaction with two receptors, CD36 (cluster of differentiation 
36) and CD47 (cluster of differentiation 47). CD36 belongs to the scavenger receptor family 
recognizing low-density lipoproteins and is involved in fatty acid and glucose metabolism as 
well as diseases associated with these, like atherosclerosis and inflammation 20. Studies in mice 
lacking CD36 or CD47 showed that TSP1 only leads to changes in NO-mediated vascular 
responses via its interaction with CD36 in the presence of CD47. However, TSP1 elicits no 
response via CD36 activation in the absence of CD47 15, 17. Additionally, in vitro analysis has 
found that TSP1’s inhibitory signal on NO-stimulated cGMP production is 100-1000 fold more 
sensitive when mediated via CD47 compared to CD36. For this reason the studies herein will 
only focus on CD47 and not CD36.  
Though the exact mechanism of this TSP1-CD47 signaling pathway is not yet 
understood, parts of this thesis demonstrate that activation of CD47 by TSP1 leads to changes in 
enzyme activity of endothelial nitric oxide synthase and changed vascular reactivity downstream. 
Interestingly, patients with gray platelet syndrome lack α-granules as well as α-granule 
constituents, like TSP1, and aggregate poorly in response to thrombin 21. Unfortunately there are 
no studies of these patients in regard to their vascular health. 
It has been shown that TSP1’s interaction with CD47, via its C-terminus, leads to platelet 
activation and, in culture, to platelet spreading22-24. TSP1 stimulated cell migration has also been 
shown to be pertussis toxin sensitive, thus blocking Gi and leading to increased accumulation of 
cAMP levels downstream. Accordingly, addition of TSP1 in the absence of pertussis toxin 
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results in decreased cAMP levels, due to active Gi 25. Further, binding of TSP1 to CD47 has been 
reported to promote apoptosis in activated T-cells. Thus by reducing the number of activated T-
cells TSP1 leads to a reduced inflammation 26. 
 
 
Figure 1. Domains of TSP1 and its interaction with CD47 and CD36 leading to inhibition of NO/cGMP 
signaling 
This schematic illustrates the interaction of TPS1 with CD36 and CD47. Binding of TSP1 to CD47 results in 
decreased cGMP levels by interfering with the classic vasodilatory pathway of NO. Reprinted from Nature 
Reviews.Cancer 2009. Vol 9 No 3:182-94 with permission from Nature Publishing Group. 
1.1.3 Structure and Ligands of CD47 
Cluster of Differentiation 47 (CD47), also called Integrin-Associated Protein (IAP), is a 50 kDa 
membrane protein that belongs to the immunoglobulin superfamily. It consists of a single IgV-
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like domain at its N-terminus, a hydrophobic stretch with five membrane-spanning segments and 
an alternatively spliced cytoplasmic C-terminus 27 (four splice variants). The length of the 
cytoplasmic tail can vary depending on tissue type. The most common cytoplasmic tail length 
observed is the second to shortest splice variant.  
CD47 is ubiquitously expressed and was first discovered in copurification studies 
involving the integrins αvβ3 from leukocytes 27. Further studies showed that CD47 interacts not 
only with αvβ3, but also with the integrins αIIbβ3 and α2β1 allowing it to interact with platelets, 
melanoma cells, ovarian carcinoma cells and smooth muscle cells 22, 28-30 31. In addition CD47 
has been shown to have complete homology to the cancer antigen, OV-3, further fueling research 
of its role in angiogenesis and cancer biology.  
Attempts to identify additional Rhesus polypeptides on erythrocytes led to the discovery 
of Integrin-Associated-Protein as CD47 making the term “Integrin-Associated-Protein” a 
misnomer since erythrocytes lack integrins. In addition to its function in integrin signaling, two 
other ligands of the CD47 receptor have been identified, thrombospondin 32 and Signal–
Regulatory Protein α (SIRPα)33. SIRPα is a transmembrane protein involved in cell to cell 
communications by recruiting specific tyrosine phosphatases (SHP-1, SHP-2)34-36. These in turn 
regulate binding of the protein superfamily Ras and of the “Ras-like” protein superfamily, Rho. 
SIRPα is thus involved in regulation of cell proliferation, migration and apoptosis.  CD47-SIRPα 
signaling has also been shown to be important in the immune system37-38. Binding of 
macrophages that express SIRPα, to the CD47 receptor expressed on red blood cells, leads to 
inhibition of their phagocytosis 39-40. 
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1.1.4 Signaling of CD47 
The various roles of CD47 activation include, but are not limited to, platelet activation, leukocyte 
motility, adhesion, migration, and phagocytosis 41. For example, cells that lose CD47 expression, 
as happens during apoptosis, get cleared through phagocytosis42. In neurons and T-cells 
expression of CD47 has been shown to lead to caspase-independent apoptosis 42-43. 
 Original studies on CD47 focused on its role in integrin signaling22, 30, 44. Activation of 
integrins via activation of CD47 has been shown to lead to cross activation of other integrins and 
downstream signaling cascades resulting in changed cell migration 45. 
CD47 signaling has also been reported to involve G-proteins, since activation of CD47 
leads to pertussis toxin sensitive cellular responses establishing a role for Gi in the signaling 
cascade. Copurification studies were able to pull down Gi associated with CD47. It has been 
proposed that the integrin-CD47-Gαi complex resembles and functions as a heptahelical receptor 
(i.e. G protein coupled receptor) 45-46. However, not all cellular responses that involve CD47 
activation are G-protein mediated. 
1.2 NITRIC OXIDE 
1.2.1 Chemistry of Nitric Oxide 
The gas nitric oxide (NO) is a free radical and a one electron oxidant. With nitrogen containing 
five valence electrons and oxygen six, NO has a total of eleven valence electrons (:N≡ .O:). 
Since each orbital holds only two electrons with opposing spin, one electron is left over. This 
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unpaired electron weakens the triple bond between nitrogen and oxygen by one-half bond. The 
reason that two NO molecules don’t combine to yield dinitrogen dioxide (O=N-N=O) lies in the 
weakness of the single bond holding both nitrogen molecules together. At room temperature this 
bond is broken by the thermal energies. As a free radical, NO does not easily react with organic 
molecules whose orbitals are already filled with two electrons of opposite spin. These reactions 
involve high activation energies and are generally slow, yielding an organic molecule with 
another left over electron. NO is much more likely to react with other radicals generating other 
highly reactive intermediates. Nitric oxide will readily react with oxygen which has two unpaired 
electrons of parallel spin (.O-O.) yielding a nitrosyldioxyl radical, peroxynitrite (ONOO.). The 
reaction of NO with superoxide to form peroxynitrite proceeds at a rate that is six times faster 
than superoxide dismutase’s ability to quench superoxide. NO also reacts easily with transition 
metals and can react with the ferric (Fe3+) as well as the ferrous (Fe2+) form. These nitrosated 
compounds are called nitrosyl compounds. 
Under physiologic, non-stress conditions NO acts as a signaling molecule at dilute 
concentrations of 10-400 nM with a short half-life and the ability to diffuse over 100 µm. As 
hydrophobic gas, NO crosses the cell membrane as easily as oxygen or carbon dioxide requiring 
neither channels nor receptors. In addition, NO has a higher diffusion coefficient than oxygen, 
carbon dioxide, or carbon monoxide and thus becomes an ideal messenger. It was originally 
thought that the reaction of NO with oxygen, generating the toxic nitrogen dioxide, was 
responsible for its short half-life. However, the rate of that reaction is too slow to account for 
this. The concentration of NO available in a biological system dictates what chemistry it will be 
able to participate in and these reactions differ a lot under conditions that produce cytotoxic 
levels of NO (i.e. mM concentration produced by iNOS) 
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This dissertation focuses on NO as signaling molecule and will address the reactions that 
are important in this context. Three key reactions of NO have been identified: 
1) Heme-Fe2+ + .NO ? heme-Fe2+ -NO        
This reaction describes the binding of NO to a ferrous heme iron in a protein and 
elucidates the mechanism of how guanylate cyclase is activated by NO. It has been 
reported that 10 nM of NO are able to activate guanylate cylase in smooth muscle 
initiating the classical pathway leading to vasodilation 47.  
2) Hb-Fe2+ -O2  +  .NO ? Hb-Fe2+OONO ? Hb-Fe3+  + NO3-       
This reaction describes the irreversible destruction of NO. Nitric oxide reacts with 
oxyhemoglobin or oxymyoglobin to produce nitrate. Therefore, the NO produced in 
the endothelium that will diffuse into the lumen of the vessel will be destroyed by red 
blood cells. 
3) .NO  +  .O-O:- ? ONOO-        
In this irreversible and very fast reaction NO reacts with superoxide generating 
peroxynitrite. This reaction can easily explain the short half-life of NO.  
Chemical experiments using NO gas on the lab bench can give us many insights into the 
kinetics and types of reactions possible for this gas. However, the study of NO chemistry can 
differ from its physiologic chemistry. Scientists have often published contradictory results when 
studying nitric oxide. They are foremost limited by the technology that exists to measure NO 
levels accurately.  In addition, the exact location, timing and rate of production of NO in a 
physiologic setting have to be carefully considered. 
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1.2.2 Signaling Pathways of NO  
Nitric oxide was first identified as mediator of endothelium-dependent vasodilation 48. However, 
we now know that this “classic” NO-sGC-cGMP pathway is not only important in vascular 
relaxation, but also in neurotransmission as well as inhibition of platelet aggregation. As an 
initiator of this pathway NO binds to the ferrous state of the heme moiety in guanylate cyclase 
(sGC) forming a five coordinate ferrous nitrosyl complex 49. This is followed by additional NO 
binding to a non-heme site leading to activation of the enzyme, and a subsequent increased 
production of guanosine 3’,5’-cyclic monophosphate (cGMP) 50. However, activation of sGC can 
also occur by NO-independent mechanisms 51. The rise in cGMP leads to inactivation of myosin 
light chain kinase via its phosphorylation by cGMP-dependent protein kinase.  This in turn leads 
to decreased phosphorylation of myosin light chain and as a result, stabilization of the inactive 
form of myosin and vasorelaxation 52-54. 
Vasorelaxation is just one of the physiologic responses due to the activation of sGC. 
Increased levels of cGMP also modulate phototransduction as well as fluid and electrolyte 
homeostasis 55-56. Binding of NO to sGC increases its activity by more than 200 fold. On the 
other hand, it is the enzymatic activity of phosphodiesterases that stops sGC activity by 
hydrolyzing cGMP to GMP 57.  
1.2.3 Nitric Oxide and Disease 
NO released by the endothelium functions to maintain vascular tone, blood viscosity (preventing 
the formation of abnormal blood clots) and has anti-inflammatory action. For these reasons the 
lack of NO or the lack of its bioavailability can give rise to many vascular diseases. The reaction 
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of NO with superoxide is one common reason for the reduction in bioavailable NO. Under 
healthy conditions, superoxide is eliminated by superoxide dismutases (SOD) 58. However, the 
interaction of NO with O2- is six times faster than the reaction of O2- with SOD 59 and thus 
increased levels of O2- lead to increased production of peroxynitrite. 
The protonation of peroxynitrite subsequently yields peroxynitrous acid which 
decomposes into nitrogen dioxide radical and hydroxyl radicals 59. The nitrogen dioxide radical 
leads to the production of nitrophenols and further downstream to the formation of 3-
nitrotyrosines at tyrosine residues, a marker of peroxynitrite formation. The source of O2- 
production is the result of enzymes like NADPH oxidases, xanthine oxidase, lipoxygenase and 
even uncoupled NOS 60-63. During uncoupling eNOS, a homodimer, separates into its monomeric 
units while maintaining enzymatic activity. This leads to inefficient electron transfer resulting in 
the production of superoxide. Finally a range of cardiovascular and metabolic diseases in people 
have been associated with decreased NO production/bioavailability including peripheral vascular 
disease, diabetes, hypertension, stroke and myocardial infarction. 
1.3 NITRIC OXIDE SYNTHASE 
NO is produced endogenously by three enzymes, endothelial nitric oxide synthase (eNOS, 
NOS3), neuronal NOS (nNOS, NOS1), and inducible NOS (iNOS, NOS2)64-66. However, NO 
can also be produced enzyme independently 67-68. While eNOS is constitutively expressed 
throughout the vasculature by endothelial cells 69-71(including cardiac myocytes, platelets, mast 
cells, leukocytes, erythrocytes, renal epithelium), nNOS is localized to the neuronal tissue. 
Activation of eNOS and nNOS lead to the production of pM amounts of NO that exert a range of 
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beneficial effects on the vasculature. This stands in contrast to iNOS which on induction by 
inflammatory stimuli is able to produce high levels of NO with cytotoxic effects (mM 
concentrations). This thesis will focus on eNOS 72-73, physiologic NO signaling and the 
downstream vasodilatory events mediated by this pathway. 
1.3.1  Enzyme Structure  
Endothelial nitric oxide synthase catalyzes the reaction from L-arginine to produce L-citrulline 
and NO with a Km for L-arginine of 2.9 µM 74. Since L-arginine levels are 100 fold higher in 
vivo and tissue culture medium it does not easily become the rate limiting factor 75-76. eNOS is a 
large dimer of about 140 kDa and both monomers are tightly linked through the heme domains.  
eNOS consists of two functional domains 77-78. One is the catalytic domain at the N-terminal that 
binds the heme prosthetic group (iron protoporhyrin IX) and the permanently bound redox 
cofactor tetrahydrobiopterin (BH4), the other domain is located at the C-terminal and binds 
FMN, FAD and NADPH 79. BH4 is indispensable for eNOS activity 80. The crystal structure for 
eNOS is known and it has been reported that BH4 stabilizes eNOS by binding to the dimer 
interface 81-84. Further, the dimer interface contains a zinc ion that is tetrahedrally ligated by two 
Cys residues, one in each monomer, which are also responsible for the binding of BH4 to the 
enzyme. Substrate binding occurs at the active heme site via extensive hydrogen bonding81-84. 
For NO production to occur eNOS requires oxygen and NADPH. Electron flow occurs from 
NADPH to FAD, to FMN and last to the heme 85.  
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 Figure 2. Schematic of factors required for endothelial nitric oxide synthase function 
This schematic illustrates the various elements required for full endothelial nitric oxide synthase activity. Reprinted 
from Nature Cardiovascular Medicine 2008. Vol 5No 6:338-347 with permission from Nature Publishing Group. 
1.3.2 Regulation of Enzyme Activity of eNOS 
The regulation of eNOS’s enzyme activity is complex occurring on a transcriptional, 
posttranscriptional as well as posttranslational level 86-87. Since this thesis focuses only on acute 
changes in NO production and thus eNOS activation, transcriptional regulation will not be 
discussed here. Some posttranslational modifications include changes in phosphorylation state, 
interaction with a variety of factors, or even by self- nitrosylation of its own cysteine residues. 
Under unstimulated conditions eNOS is bound to caveolae in the cell membrane via acyl anchors 
produced by myristoylation and/or palmitoylation reaction of its N-terminus. Caveolae are 
important cellular regulatory sites where many multifunctional receptors, like G-protein- 
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like receptors, are sequestered and where signaling pathways converge via protein-protein 
interactions or protein-lipid interactions 88-91. 
Binding of calmodulin to eNOS is one requirement to obtain full enzyme activity by 
allowing electron flow between its two catalytic domains. Calmodulin binding is dependent on 
changes in intracellular calcium levels. Stimuli, like bradykinin or acetylcholine, activate G-
protein-dependent pathways leading to the production of diacylglycerol (DAG) via 
phospholipase C (PLC) and subsequent inositol 1,4,5,-triphosphate (IP3) mediated calcium 
mobiliziation via ion channels 92. 
In addition to calmodulin binding, eNOS activity is regulated by phosphorylation of 
specific serine and threonine residues (Ser1177, Ser635, Ser617 are stimulatory, Thr495, Ser 116 
are inhibitory). Phosphorylation at Ser1177 has been shown to affect eNOS activity two-fold: 1. 
by increasing internal electron flow and 2. by inhibiting calmodulin dissociation. Adding 
complexity to the regulation of eNOS, various products of major signaling pathways can 
phosphorylate Ser1177, i.e. protein kinase B (akt), cyclic AMP-dependent protein kinase (PKA), 
AMP-activated protein kinase (AMPK), cGMP-dependent kinase (PKG), calcium/calmodulin-
dependent protein kinase II 93-100. It has been reported that PI3K recruits Akt to the membrane for 
phosphorylation, a requirement for subsequent phosphorylation of eNOS. 
S-nitrosylation of eNOS has been shown to occur via its own NO production and 
subsequent inhibition 101-103. During maximal NO production eNOS is denitrosylated. 
Nitrosylation or denitrosylation has been shown to depend on the cellular location of eNOS and 
several different mechanisms have been postulated to explain this inhibitory effect 101-103 104. 
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Caveolins are small membrane bound proteins. Caveolin 1 (cav-1) which is ubiquitously 
expressed in endothelial cells, leads to localization of eNOS to caveolae 105-109 and by direct 
protein interaction with eNOS sterically blocks the binding of calmodulin. 
Endoglins are glycoproteins highly expressed in endothelial cell membranes, dominantly 
in caveolae. They stabilize eNOS by promoting its association with Heat shock protein 90 
(HSP90) 110-113. Partial loss of endoglin has been shown to cause a decrease in the half-life of 
eNOS protein, as well as a switch in production from NO to superoxide 110-113.  
HSP90 is a protein involved in the folding and trafficking of other proteins. Binding of 
HSP90 to eNOS stimulates its activity by enhancing the affinity for calmodulin binding to eNOS 
and balances the production of NO over superoxide. In addition HSP90 affects eNOS activity 
indirectly by binding active and inactive Akt and is required for the interaction between Akt and 
eNOS. HSP90 also protects PI3K degradation and inhibits Akt deactivation. Interestingly HSP90 
and Akt activate eNOS also in a calcium independent manner 114-118. eNOS itself has been shown 
to have a negative feedback mechanism where the production of NO causes s-nitrosylation of a 
specific cysteine residue leading to eNOS-HSP90 disruption 119. 
Another regulator of eNOS is shear stress 120. This frictional force of blood flow has been 
shown to regulate eNOS activity. Flow rates of 10-15 dynes cm-2 in humans and between 30-35 
dynes cm-2 in mice and rats are sufficient to increase eNOS activity and production. A shear 
stress-response element has been identified in the eNOS promoter region 121-122. Within 
endothelial cells the cytoskeleton has also been identified as  a factor of mechanotransductation 
and changes in flow and shear stress rapidly alter calcium flux and eNOS phosphorylation 123. 
Additional regulation of eNOS activity is achieved by the action of phosphatases. 
Dephosphorylation of inhibitory or stimulatory residues can increase or decrease enzyme activity 
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respectively. Activity is also determined by subcellular localization of eNOS and as such various 
eNOS associated proteins have been identified that are involved in its trafficking like important 
interaction with cytoskeletal actin. The complexity of eNOS regulation is enormous and 
probably as such also a good indicator of its importance in our vasculature. 
1.3.3 Agonist Dependent Activation of eNOS 
Binding of a variety of agonists to the plasma-membrane leads to eNOS activation. This occurs 
mostly by activation of two downstream pathways that either activate Akt, or stimulate calcium 
release or do both. Vascular endothelial growth factor (VEGF) is one such physiologic agonist 
leading to rapid eNOS activation by binding the VEGF receptor 2 (VEGFR2, a tyrosine kinase). 
Subsequent activation of PLC in turn leads to IP3 mediated eNOS activation and is described as 
“immediate” response. In parallel, eNOS activation via DAG and PKC is called “delayed” 
response. Binding to VEGFR2 also leads to increased downstream PI3K and Akt–mediated 
immediate eNOS activation 124-128. 
Other agonists lead to eNOS activation via binding to G-protein coupled receptors 
(GPCR). For example, bradykinin binding to the GPCR bradykinin receptor B2 leads to calcium 
mediated eNOS activation. Another common pharmacologically used activator is acetylcholine 
(ACh), a neurotransmitter that binds the muscarinic M3 receptor followed by calcium dependent 
enzyme activation. Histamines, sphingosine-1-phosphate, as well as estrogen, are further 
examples of agonists binding to GPCRs and subsequent calcium mediated eNOS activation 129. 
Natriuretic peptide will lead to eNOS activation by binding to its own receptor that has been 
shown to involve G-proteins and is also followed by downstream activation of calcium channels 
130. 
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It has further been shown that low, though still physiologic, oxygen levels (i.e. PO2 of 
20-40 mmHg) can inhibit eNOS with subsequent reduced eNOS protein expression 131. However, 
further research demonstrated the opposite effect and eNOS expression seems to be tissue 
specific 132-133. 
1.3.4 Physiology and Biological Role of eNOS 
 eNOS functions to produce nitric oxide. The various effects of NO are discussed above (Nitric 
Oxide section). One main result of NO produced by eNOS is its control of vascular tone 134-137. 
Diffusion of NO into the smooth muscle layer of the vessel wall leads to the activation of sGC 
and sGC increases conversion of GTP to cGMP. This increased cGMP production in turn starts a 
signal transduction cascade leading to smooth muscle relaxation (hypopolarization) 138-140.  
Besides producing nitric oxide eNOS activity leads to the production of citrulline which is 
catalyzed in the urea cycle to argininosuccinate. Citrulline has also been shown to lead to 
posttranslational modifications, i.e. citrullination and is used as biomarker of autoimmune 
diseases, like rheumatoid arthritis 141. 
1.3.5 eNOS in Disease 
Vascular disease has been associated with a decrease in bioavailability of NO which is reported 
to be either the cause or the result of endothelial dysfunction. These diseases include 
atherosclerosis, diabetes and hypertension. Decreased NO is also associated with decreased 
angiogenesis and apoptosis. In atherosclerosis, peripheral vascular diseases, stroke and coronary 
heart disease, endothelial dysfunction is regarded as an initiator. Age-induced loss of normal 
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endothelial function, leads to loss of NO production from eNOS and under some conditions to 
upregulated NO production from iNOS 142. For example, vessels of cholesterol fed animals have 
less vasoactive responses and administration of L-arginine, or tetrahydrobiopterin attenuates the 
formation of atherosclerotic lesions 143-149. Regardless, the net effect is an overall decrease in 
physiologic (pM) levels of NO and suppression of the pro-flow and antithrombotic role 
endogenous NO exerts. 
Diabetes mellitus is also characterized by endothelial dysfunction and the role of 
unbalanced bioavailability of NO has been well documented 150-151 152-153. For example, 
endothelial cells isolated from diabetic rats have reduced levels of tetrahydropterin leading to 
reduced NO but increased superoxide production 154-156.With its vasodilatory effect on the 
vasculature NO is crucial in blood pressure control 157. In hypertension NO-mediated 
vasodilation is impaired. However, it is not clear if this is due to a reduction in NO synthesis or 
increased consumption of NO. In both animal and human studies blockade of eNOS activity with 
the competitive NOS inhibitor L-NAME uniformly results in increased blood pressure. 
Conversely, exogenous NO in the form of the commercial therapeutic Bidil has been found to 
significantly lower blood pressure in a subset of hypertensive patients. Efforts at enhancing 
physiologic (low level) NO production through increasing eNOS activity or stimulating cGC 
directly are areas of robust research. 
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1.4 PHYSIOLOGY OF VASCULAR TONE 
1.4.1 Vessel Anatomy and Physiology 
The anatomy of an artery is divided into three major structures, the tunica intima, the tunica 
media and the tunica adventitia 158. The tunica intima is made up of endothelial cells lining the 
luminal area of the vessel, also called intima. On the side opposing the lumen endothelial cells 
are anchored to the basal lamina which is further composed of the internal elastic lamina. In 
larger animals, including humans, this sub-endothelial layer is made up of smooth muscle cells 
and aids in maintaining vascular integrity.   
The tunica media mainly consists of smooth muscle cells and elastin. The elasticity of a 
vessel is mostly due to elastin which also allows for even stress distribution across the whole 
vessel wall onto collagen fibers 159-161. 
The tunica adventitia makes up the outermost layer of the vessel wall and consists of 
collagen-rich extracellular matrix and fibroblasts. The high collagen content prevents the vessel 
wall from rupture at high pressures 162. Small blood vessels, called the vaso vasorum, originate 
from the tunica adventitia and function as energy supply for the cells in the wall. Studies of 
injury models revealed in the last decade that the vaso vasorum contains progenitor cells that are 
able to differentiate into smooth muscle cells 163-164. 
The circulatory system is divided into the pulmonary and the systemic circulation with 
the latter describing the blood supply to all tissues in the body except for the lungs. Pressures in 
the systemic circulation are high (120/80 mmHg in the human aorta) while pulmonary vascular 
pressures in the lung are low (14 mmHg at rest). Blood flow throughout the body occurs via a 
variety of vessels. Arteries are vessels with strong vascular walls that can withstand blood flow 
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under high pressure and high velocity. They are defined as carrying oxygenated blood from the 
lung to the rest of the body. It is the elasticity of the arteries that allows for large volume changes 
in the arterial branches with very little change in pressure. The aorta falls into the class of large 
arteries. These large vessels eventually lead to the smallest arterial branches, the arterioles. With 
their muscular walls the arterioles can dilate or constrict strongly and thus have the ability to 
control blood flow tremendously and in a very tissue specific fashion. Blood from the arterioles 
enters the capillaries (8 µm). These very thin walled and porous vessels function to exchange 
nutrients with tissue and interstitial fluid. The deoxygenated blood from the tissue then collects 
in the venules leading to larger vessels, the veins, leading back to the heart. Blood pressure in the 
venous system is low. Despite their thin walls these vessels are still able to dilate and constrict. 
This allows them to control blood volume by serving as an adaptable storage compartment. The 
heart then pumps the blood back into the lung for oxygenation 165. 
Under conditions of laminar/streamlined flow the conductance of blood through the 
vessels is strongly affected by the fourth power of the vessel’s diameter. This phenomenon is 
described by Poiseuille’s Law: F= πΔPr4/ 8ηl, where F is the rate of blood flow, ΔP is the 
pressure difference between the ends of the vessel, r is the radius of the vessel, l is the length of 
the vessel and η is the viscosity of the blood. Thus, because flow is directly proportional to the 
vessel radius to the fourth power, small changes in vessel diameter lead to large changes in blood 
flow 166. 
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 Figure 3. Simplified schematic demonstrating the cellular composition of blood vessels 
Blood vessels are made up of  three distinct layers; the adventitia, comprised mostly of fibroblasts; the media, made 
up of vascular smooth muscle; and the intima, comprised of a single layer of endothelial cells lining the lumen of the 
vessel. 
1.4.2 Endothelial Dependent Relaxation 
The endothelium functions to regulate angiogenesis, inflammatory responses, hemostasis, and 
permeability and is the key player in the control of vascular tone 167. Its position in the vessel 
allows it to serve as an interface between the intravascular compartments (consisting of the 
blood) on one side and the underlying vascular smooth muscle cells on the other. The 
endothelium creates therefore the possibility to respond to physical stimuli of blood flow (i.e. 
shear stress, pressure) as well as to chemical agents in the blood (i.e. hormones) by either 
transmitting the signal to the smooth muscle layer via gap junctions, channels, other signal 
transduction cascades or by releasing its own compounds (i.e. nitric oxide) that can diffuse 
 20 
across the layers. The effect on the smooth muscle layer to the endothelium is either 
hyperpolarization leading to relaxation or depolarization followed by contraction 168. 
The release of nitric oxide as well as prostacyclins (PGI2) is considered to be the main 
factor contributing to endothelium dependent vasodilation 169-170. PGI2 production is the result of 
cyclo-oxygenase mediated breakdown of arachidonic acid. Interestingly changes in vascular tone 
have also been reported in the presence of NOS and cyclo-oxygenase inhibitors, pointing to 
additional endothelial vasodilators. Various metabolites of endothelial cytochrome P450 have 
been reported to act as vasorelaxors (i.e. epoxyeicosatrienoic acids) or vasoconstrictors (i.e. 20-
hydroxyeicosatetraenoic acid) 171-173. Further, hydrogen peroxide (H2O2) can have either dilatory 
or constrictive endothelium-dependent effects. The production of superoxide, by nitric oxide 
synthases, cyclo-oxygenases, cytochrome P450 epoxygenases, NADPH oxidases as well as 
mitochondrial enzymes of the respiratory chain can lead to downstream H2O2 production in the 
endothelium174-182. Another endogenous vasodilator is CO that is produced by heme oxygenase 
1(inducible) and 2 (constitutive). It has been shown that CO production can compensate for the 
loss in NO bioavailability 183, but, on the other hand, can also inhibit NOS function. The gas 
hydrogen sulfide (H2S) which is produced enzymatically by cystathionine β-synthase and 
cystathionine γ-lyase, has been reported to have an endothelium-dependent vasorelaxant effect as 
well 184-185 though these studies used non-physiologic levels of H2S (>150 µM). The complexity 
of endothelium-dependent vasodilation is further increased by reports showing different effects 
of agents mentioned above depending on the location of the vascular bed as well as gender. In 
addition to endogenously produced endothelium-dependent vasodilators exogenous anesthesia 
related agents like cannabinoids have also been shown to lead to endothelium dependent 
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relaxation 186 and need to be taken in consideration in the clinical setting as well as in animal 
research. 
1.5 PULMONARY HYPERTENSION 
1.5.1 The Disease and Etiology of Pulmonary Hypertension 
Pulmonary arterial hypertension (PAH) is a disease/pathogenesis of the small pulmonary arteries 
that is characterized by vascular proliferation and remodeling 187-188. PAH is identified 
histologically in patients by plexiform lesions as a result of endothelial cell proliferation. In 
addition, increased proliferation of smooth muscle cells and myofibroblasts leads to medial 
hypertrophy and adventitial hyperplasia 189-192. Progressive vascular remodeling causes an 
increase in pulmonary vascular resistance. In humans PAH is defined by mean pulmonary artery 
pressures greater than 25 mmHg and a pulmonary-capillary wedge pressure of less than 15 
mmHg. Over time this increase leads to further remodeling, right heart failure and ultimately 
death 193. A diagnosis of idiopathic PAH is made when no known etiology is found 194 195.  The 
diagnosis for PAH is divided into 6 groups by the World Health Organization. In addition to 
inherited familial PAH, several diseases have been shown to lead to the development of PAH, 
such as congenital left-to-right cardiac shunts, hemoglobinopathies, human immunodeficiency 
virus infection, collagen vascular defects, significant left heart disease, chronic pulmonary 
thromboembolic diseases, and chronic lung disease and/or hypoxemia195-196.  Recent studies have 
also unraveled the important clinical finding of PAH contributing to the pathogenesis and 
increased mortality in patients with sickle cell disease 187, 197.  
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Though various types of pulmonary hypertension arise from different etiologies, they 
share common pathophysiological features including remodeling of the pulmonary vessel wall, 
vasoconstriction, and thrombosis in situ 187. Increased reactivity to vascoconstrictors and 
correspondingly decreased reactivity to vasodilators further emphasize the anatomical changes 
observed in the lung. As such impaired production of vasoactive NO or prostacyclins or over-
expression of vasoconstrictors such as endothelin-1, can alter pulmonary vascular tone and lead 
to vascular remodeling.  Alterations in these vasoactive molecules suggest that endothelial 
dysfunction plays a key role in the pathophysiology of PAH 198-202.   
The cellular and molecular events underlying the evolution of these changes and those 
that occur in response to these changes are under investigation and continue to guide the 
development of therapeutics.  A substantial number of molecules and molecular pathways have 
been implicated, but clearly the pathogenesis involves a multifactorial process 187-188, 200. 
Treatment of PAH targets vasorelaxation and the blocking and reversal of cell proliferation (i.e. 
via induced apoptosis). Nonselective vasodilators are not useful due to their dilatory effect on the 
systemic vasculature and therefore the risk of hypotension. Inhibition of phosphodiesterase-5 is a 
common therapy used to treat moderate PAH and offers several advantages. First, its expression 
is not systemic but selective to the lung and penile tissue. Secondly, due to the function of 
phosphodiesterases to breakdown the production of cGMP, inhibition of these enzymes leads to 
increased cGMP levels and thus increased vasodilation. The PDE5 inhibitor sildenafil was 
approved by the FDA as treatment for moderate PAH in 2005. In addition to ongoing trials with 
PDE5 inhibitors, PAH can be treated by calcium channel blockers, as long as the patients 
responds to the acute administration of vasoactives. Other common drugs include prostacyclin 
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analogues as well as endothelin antagonists. However, despite 16 ongoing clinical trials showing 
a clear improvement in symptoms neither of these drugs have been shown to reduce mortality 203. 
Another area of investigation is the role of potassium channels on the development of PAH.  
Decreased expression of voltage gated potassium channels as well as potassium channel 
depolarization has been associated with vasoconstriction and increased pulmonary artery smooth 
muscle cell (PASMC) proliferation187-188, 204-208.  Likewise, manipulation of these molecules and 
pathways has been the basis for the development of drug therapy 200, 209-210. 
Currently patients with PAH have a prognosis of 85% for a 1-year- survival rate in the 
US 211, up from 68% in the 1980s 193 and a median mortality rate of 5 years. The symptomatic 
outcome of PAH, independent of its cause, is on the rise worldwide 212. With the harsh survival 
prognosis for PAH, with a rise of PAH worldwide, and with only a very limited number of drugs 
available for its treatment, research focusing on PAH is imperative to our understanding of the 
disease and thus our ability to find better therapies. 
1.5.2 eNOS and Pulmonary Hypertension 
While many of the mechanisms leading to PAH are still unknown it is well established that one 
of the key initiating events is endothelial dysfunction 213-215. Importantly failure of NO mediated, 
endothelium dependent vasodilation has been well described both clinically and in experimental 
animal models of PAH 216-222. Endothelial nitric oxide synthase is the NOS most prominently 
expressed in the vasculature under healthy conditions and thus of interest in the development of 
PAH 223. Studies in eNOS null mice have shown a mild development of PAH in these mice 
exposed to room air that progresses to severe PAH when chronically exposed to mild hypoxia 
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224-225. eNOS is a tightly controlled enzyme on a transcriptional, postranscriptional, and 
posttranslational level. As such studies looking at endothelial impairment have focused on the 
regulatory factors involved in eNOS activation, including caveolin-1, heat shock protein 90, 
calcium as well as upstream regulators of eNOS activation, such as ion channels and 
AKT/protein kinase B 89, 226-230. It has been reported in PAH animal models that eNOS is 
upregulated 231-232 while the lung shows impaired NO bioactivity. Interestingly it has also been 
shown that hypoxia induced PAH leads to tight interaction between eNOS and caveolin-1, 
thereby physically blocking the enzymes from other signaling molecules 233. Others observed the 
loss of caveolin-1 and hemeoxygenase expression in severe PAH 234.  
1.5.3 Animal Models of Pulmonary Hypertension 
The newly updated classification system for PAH shows a broad range of parameters leading to 
its development 196. Not surprisingly this diversity corresponds also to a variety of histological 
features observed in patients with PAH and therefore makes the study of PAH in animal models 
more complex 235. One characteristic and defining feature distinguishing PAH from PH is the 
commonly described appearance of plexiform lesions during the late stage. However, even this 
hallmark is not always observed in all patients 236-237. Others recently further described the 
heterogeneity observed in vascular lesions in PAH 238. 
  Additionally, death from PAH is due to right heart failure and also involves loss of 
elasticity in larger conduit vessels. This stiffening adds further complexity to the study of PAH in 
animal models. 
The two most commonly used animal models of PH are the chronic hypoxic exposure 
model and the monocrotaline injury model. For chronic hypoxic exposures (10% for 3 weeks) 
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the investigator chooses between normobaric or hypobaric exposure with the latter resembling 
high altitude induced PAH. Chronic hypoxic exposure is commonly used in rodent models with 
reproducible outcomes. In this model rats initially demonstrate increased muscularization of 
small, previously non-muscular arterioles which leads to the progressive thickening and 
obliteration of muscularized precapillary arteries. In addition, inflammation, a rise in 
chemokines, fibrosis and stiffening of large conduit arteries have been observed in the hypoxic 
model. Interestingly rats develop right ventricular hypertrophy but not right ventricular heart 
failure. 
Chronic hypoxic exposure in mice leads to increased pulmonary artery pressures but to 
less vascular remodeling than observed in rats. Differences in gene expression due to chronic 
hypoxic exposure have been reported between mice and rats 239. However, there are also 
significant differences in response to chronic exposure between mouse strains 240. Though 
vascular remodeling is less in mice exposed to chronic hypoxia they nonetheless do show 
changes as seen in rats, including muscularization of non-muscularized vessels, thickening of 
arteries, fibrosis and stiffening of the vessels 241-242. PAH reversal has been observed in rodents 
by Stenmark (unpublished) when returned to normoxic conditions, which clearly differs from the 
human progression of PAH.  
Monocrotaline injury requires either ingestion or subcutanous injection of this toxic 
pyrrolizidine alkaloid and is considered an acute damage model affecting also the peripheral 
vasculature. The compound requires enzymatic activation by the rat. Mice unfortunately lack that 
enzyme and have recently been injected with the activated compound. The exact mechanism of 
how monocrotaline induces PAH is not known, but increased vascular remodeling and a rise in 
pulmonary pressures is usually observed within 1-2 weeks after the initial dose. Interestingly 
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monocrotaline leads to sequestration of eNOS away from caveolae and thus causes a reduction of 
NO levels though eNOS protein levels stay unaffected 243. Several groups suggest that adventitial 
inflammation contributes greater to the progression of PAH than the endothelium 164, 244-245. 
Besides an effect on the lung vasculature, there have been reports on liver and kidney damage as 
well as changes in veins 244-246. Interestingly there have been more than 30 compounds found that 
prevent and/or reverse monocrotaline-induced PAH. 
In addition to these two classic models, investigators have used modifications to better 
recapitulate the human condition. Examples in rats include a combination of monocrotaline 
injection as well as pneumonectomy 247 resulting in the formation of neointima due to the 
changes in hemodynamics caused by the pneumonectomy 248. Others have developed a severe 
model of PAH by inhibiting the VEGF receptor 249 with a pharmacological agent, Sugen 5416, in 
combination with chronic hypoxic exposures. They observed irreversible precapillary arterial 
endothelial proliferation in these rats. As with any model, none is perfect and investigators have 
to carefully consider their choice of model as well as the bias introduced into their results based 
on this choice. We have chosen the murine model of chronic hypoxic exposure (3 weeks at 10% 
Oxygen), since it is well established, produces reproducible results, and gives us the advantage to 
use transgenic animals. 
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1.6 STATEMENT OF HYPOTHESIS 
In 1998 three scientists received the Nobel Prize in Physiology and Medicine for their discovery 
of NO as a signaling molecule in the cardiovascular system. Dr. Furchgott observed that 
relaxation of isolated vessels was endothelium dependent leading to the release of an 
Endothelium Derived Relaxing Factor (EDRF). Dr. Ignarro discovered that EDRF is NO, since 
exposure of NO or EDRF to hemoglobin resulted in an identical shift using spectral analysis and 
Dr. Murad had uncovered the mechanism of NO’s dilatory action allowing for a whole new class 
of drug targets. Now we know that NO is produced by the endothelial enzyme nitric oxide 
synthase (eNOS) and that the lack of NO or the lack of its bioavailability is intimately involved 
in a wide range of diseases, like atherosclerosis, diabetes, hypertension or stroke. The initiating 
events of these vascular diseases are referred to as endothelial dysfunction. 
Thrombospondin 1, an extracellular matrix protein released from platelets upon injury, 
has been studied in regard to tumor angiogenesis. Dr. Isenberg discovered that TSP1 antagonizes 
the NO-mediated-cGMP-dilatory pathway in smooth muscle and endothelial cells via the 
ubiquitous receptor CD47 leading to decreased levels of cGMP12, 15-16. In addition to its anti-
angiogenic effects TSP1 was shown to modulate blood pressure as well as cardiac responses to 
vasoactive stress 14, 18. Additionally, TSP null animals demonstrated enhanced shear-dependent 
blood flow compared to wild type animals. In the absence of disease TSP1 occurs in only two 
locations in the vascular system – as a soluble protein in the blood and preformed in the alpha 
granules of platelets. However, with a molecular weight of 450 kD TSP1 is too large to cross the 
subendothelial basement membrane of arteries and thus doesn’t explain the observed differences 
in blood flow in the null animals. 
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We hypothesized that TSP1 directly modulates eNOS activity and, thus, endothelium-
dependent relaxation of blood vessels. Further, we were interested in how the inhibitory effects 
of TSP1 on eNOS would translate in a disease setting, specifically pulmonary hypertension. 
Thus, we hypothesized that the lack of TSP1 would protect TSP1 null mice from the 
development of pulmonary hypertension.  We used chronic hypoxic exposure of mice to model 
pulmonary hypertension. In addition, we were fortunate to have access to lung tissues from 
patients with or without PAH, that were compared to the results obtained in the hypoxic rodent 
model. 
Understanding the role and mechanism of action of TSP1 in healthy and disease states 
will open up new routes for drug development and provide insight into the molecular 
mechanisms underlying the effects of current therapies targeting the NO/cGMP pathway. 
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2.0  MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1 Maintenance and Storage 
Human umbilical cord endothelial cells (HUVEC) (Lonza, Walkersvile, MD) were grown in 
EGM2 basal media supplemented with various growth factors and fetal bovine serum (EGM-2 
SingleQuots, Lonza). Cells were maintained under humidified conditions at 37°C and 5% CO2 
and medium was changed every 48 hrs.  
To passage cells, they were rinsed with Hanks’ Balanced Salt Solution (HBSS) 
(Invitrogen), followed by incubation in 2 ml trypsin/EDTA solution (Lonza, Walkersville, MD) 
for 3-4min per T75 flask. The enzyme was then neutralized by addition of 10 ml complete 
media. Cells were pelleted via centrifugation for 5 min at 4°C and 1200 rpm and reseeded at a 
ratio of 1:3. Cells were only used up to passage nine.  
For long term storage pelleted cells were resuspended in complete media containing 10% 
dimethylsulfoxide (DMSO) (Sigma-Aldrich) and 10% additional fetal bovine serum (Lonza, 
Walkersvile, MD). One million cells were aliquoted per storage vial which was cooled for 24 hrs 
in -80 °C and then transferred to liquid nitrogen. 
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2.1.2 Common Experimental Treatments 
For all endothelial cell experiments cells were serum starved in serum and growth factor free 
media containing 0.1% BSA for 24 hrs prior to treatment. Addition of TSP1 (2.2 nM) was 
always performed by preincubating cells or vessels for 15 min prior to other treatments. 
2.2 CALCIUM IMAGING 
2.2.1 Determination of Calcium Flux in Cells 
Agonist-induced Ca2+ release was monitored in endothelial cells in the presence or absence of 
2.2 nM TSP1 or other treatment agents using live cell imagining. For single-cell imaging, 
HUVEC were grown on gelatin-coated 35mm glass bottom dishes (MatTek Corp., MA) and 
serum starved with 0.1% BSA 24 hrs prior to experiments. Cells were loaded with 5 µmol/L 
Fluo-4AM ester (excitation at 488 nm, Molecular Probes, Invitrogen) for 30 min at 37°C in 
Hanks buffer solution (with 1.88 mmol/L fresh CaCl2 and 20 mmol/L HEPES) followed by 2 
washes with Hanks buffer and incubation at room temperature in the dark for an additional 20 
min. Images were acquired every 3 sec on a Zeiss LSM 5 confocal microscope (Carl Zeiss, 
Thornwood, NY) at 20X with scan speed of 8.5 and a resolution of 256x256. Data were analyzed 
using software LSM Pascal 3.2 obtaining relative changes in fluorescence intensity compared to 
baseline. We added plain buffer 1 min prior to addition of the agonist ionomycin (3 µmol/L, 
Invitrogen). If cells showed changes in calcium flux due to buffer addition, they were excluded 
from the analysis.  
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 2.2.2 Determination of Calcium Flux in Mouse Aorta 
For en face calcium measurements 12 week old male C57Blk6 mice were euthanized by cervical 
dislocation. The abdominal vena cava was incised and the animal perfused via the heart using 
Krebs-buffer. The thoracic aorta was isolated and loaded for 1 hr with 5 µM Fluo-4AM 
(excitation at 488 nm, Molecular Probes, Invitrogen), followed by several washes in Hanks’ 
buffer (plus 1.8 mM CaCl2 and 20 mM HEPES at pH 7.4). Vessels were then opened lengthwise 
under a dissection microscope, secured face down onto MatTek dishes and incubated for 30 min 
in the dark. Aortic segments were transferred to the microscope stage on a Zeiss LSM 5 confocal 
microscope (Carl Zeiss, Thornwood, NY)  and images were acquired every 3 sec at 10x 
magnification and a resolution of 512x512. Stimulation with 3 µmol/L ionomycin (Invitrogen) 
resulted in a fluorescence intensity wave traveling along the vessel. Therefore data were 
analyzed using the area under curve over time over several selected regions of interest on the 
vessels. Initial data analysis was performed using LSM Pascal 3.2 software and subsequent 
calculations were performed in Graphpad Prizm. 
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2.3 METHODS FOR THE STUDY OF PROTEIN EXPRESSION 
Table 1. Buffers 
Buffer Protocol Materials 
SDS 
Electrophoresis 
Buffer 
Western Blot 25mM Tris Base, 250mM Glycine (pH8.3), 0.1% SDS 
 
Stacking Buffer Western Blot 0.5M Tris Base, 0.4% SDS , pH 6.8 
Resolving Buffer Western Blot 1.5M Tris Base, 0.4% SDS, pH 8.8 
Polyacrylamide 
Separating Gel 
10% 
Western Blot 2.5ml 30% Acrylamide, 1.875ml Resolving Buffer, 
3.125ml H2O, 50 µl 10% ammonium persulfate, 10 µl 
TEMED 
Polyacrylamide 
Separating Gel 8% 
Western Blot 2.0ml 30% Acrylamide, 1.875ml Resolving Buffer, 
3.625ml H2O, 50 µl 10% ammonium persulfate, 10 µl 
TEMED 
Polyacrylamide 
Stacking Gel 
Western Blot 650µl 30% Acrylamide, 1.25 ml Stacking Buffer, 3 ml 
H2O, 25µl 10% Ammonium Persulfate, 5µl TEMED 
Transfer Buffer 10x Western Blot 
in 2L, 288 g Glycine, 60g Tris Base, fill with H2O 
Laemmli Buffer 6x Western Blot 7ml Stacking Buffer, 30% glycerol, 10% SDS, 0.6M DTT, 
0.012% bromophenol blue, H2O till 10ml final volume 
Lysis Buffer Western Blot 50mM tris, 1% NP‐40, 1mM EDTA, 125mM NaCl, 2.54 
mM Deoxycholic Acid 
TBST Buffer Western Blot 100mM Tris Base, 150mM NaCl, 0.1% Tween 20 
IP-Lysis Buffer Coimmunoprecipitation 50mM Tris HCl pH 7.5, 0.1mM EDTA, 0.1mM EGTA, 
0.1%SDS, 0.1% Deoxycholic Acid, 1% NP‐40 
K-PSS Buffer Myograph 4.7mM Sodium Chloride, 100mM Potassium Chloride, 
1.18mM Potassium Phosphate, 1.17mM Magnesium 
Sulfate, 14.9mM Sodium Bicarbonate, 5.5mM 
Dextrose, 0.026 EDTA, 1.6mM Calcium Chloride, 
pH7.4 
PSS Buffer 
 
 
Myograph 130mM Sodium Chloride, 4.7mM Potassium Chloride, 
1.18mM Potassium Phosphate, 1.17mM Magnesium 
Sulfate, 14.9mM Sodium Bicarbonate, 5.5mM 
Dextrose, 0.026 EDTA, 1.6mM Calcium Chloride, pH 
7.4 
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2.3.1 Isolation of Total Proteins 
Cells were rinsed once with cold HBSS, scraped in lysis buffer (Table1) supplemented with a 
protease inhibitor cocktail (Sigma), 20 mM sodium fluoride, 1 mM sodium pyruvate, 5 mM   
orthovanadate and collected in tubes. After rotating for 1h at 4°C, cell lysates were sonicated 3 
times for 3 sec on ice and centrifuged for 15 min at 14,000 g. The supernatant was transferred to 
a new tube and total protein content was determined using the DC Protein Assay (BioRad) which 
included a BSA standard curve. Absorbance was read at 750 nm and protein content determined 
according to the Protein Assay’s instructions.  
For protein isolation from tissue either fresh or frozen samples were homogenized in lysis 
buffer (Table1) using an electric glass dounce homogenizer followed by 1h rotation at 4°C. The 
same protocol was then followed as described above for cells. 
2.3.2 Western Blot Analysis 
To determine the expression of one specific protein in cell or tissue lysates, samples of equal 
total protein content (30 µg) were suspended in Laemmlie Buffer (Table1), boiled for 5 min and 
resolved on a 10% SDS –PAGE (Mini-PROTEAN Tetra Cell, BioRad) at 100 V. The gel was 
allowed to equilibrate for 15 min in Transfer Buffer (Table1) and transferred onto nitrocellulose 
membrane (BioRad) in a Mini-Trans-Blot Electrophoretic Transfer Cell (BioRad) for 1.5 hrs at 
4°C and 100 V. The membrane was blocked for 30min in blocking buffer to avoid non-specific 
binding (Odyssey, 927-40000) followed by addition of primary antibody (Table2) over night at 
4°C. The membrane was washed three times for 5 min in TBST (Table1) and incubated for 1 h in 
infrared secondary antibody. The blot was visualized after 3 more 5 min washes in TBST 
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(Table1) using the Odyssey Infrared Imaging System (Licor). The intensity of the bands were 
either quantitated using the Odyssey software or Image J (rsbweb.nih.gove/ij) 
 
 
Table 2. Antibodies 
Antigen Protocol Primary Antibody Source/Dilution 
Caveolin‐1  Western  Rabbit anti‐Caveolin‐1 Santa Cruz, 1:5000, Cat.No. Sc‐894
Hsp90  Western  Mouse anti‐HSP90, BD Bioscience, 1:1000, Cat.No. H38220
Akt  Western  Rabbit anti‐akt, Cell Signaling, 1:1000, Cat. No. 9272
Phospho‐akt (Ser473) 
 
Western  Rabbit anti‐phospho‐akt, Cell Signaling, 1:1000, Cat. No. 9271
actin  Western  Rabbit anti‐β‐Actin, Cell Signaling, 1:1000, Cat. No. 4967
Phospho‐eNOS 
(pS1177) 
 
Western  Mouse  anti‐Phospho‐eNOS,  BD  Bioscience,  1:1000,  Cat.No. 
612392 
eNOS  Western  Mouse anti‐eNOS, Invitrogen, 1:1000, Cat.No. 33‐4600
eNOS  Western  Rabbit anti‐eNOS, Santa Cruz, 1:1000, Cat.No. sc‐654
Thrombospondin  Western  Mouse anti‐Thrombospondin, Abcam, 1:1000, Cat.No. ab1823
Nox4  Western  Mouse anti‐nox4, Abcam, 1:1000, Cat.No. ab1823 
Nitrotyrosine  DAB Staining Rabbit anti‐Nitrotyrosine, Millipore, 1:100, Cat.No.ab5411
4‐Hydroxynonenal 
 
DAB Staining Goat anti‐4‐Hydroxynonenal, Abcam, 1:100, Cat.No. ab20953
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2.3.3 Coimmunoprecipitation of Protein Complexes 
Cells were lysed in IP lysis buffer (Table1) supplemented with a protease inhibitor cocktail 
(Sigma), 20 mM sodium fluoride, 1 mM sodium pyruvate, 5 mM orthovanadate, collected in 
tubes and treated as described in 2.3.1. above. 500 µg of total protein per sample were incubated 
with 4 µg total eNOS antibody (Table2) and rotated for 2 hrs at 4°C. Meanwhile protein A –
Sepharose beads (Sigma) were washed 3 times in IP Lysis Buffer (Table1) to eliminate storage 
alcohol (50 µl bead-slurry per sample). After incubation in eNOS antibody 50 µl of bead-slurry 
was added to samples followed by rotation for 1hr at 4°C. Samples were centrifuged for 1min at 
9000 rpm and resuspended in 500 µl IP-Lysis Buffer (Table1). After three 15 min washes 
samples were suspended in 2x Laemmli Buffer (Table1), boiled 5min and spun for 15 min at 
14000 rpm. 
The supernantant of each sample was then resolved on SDS-Page as described in 2.3.2 
above and blotted for proteins of interest.  
2.3.4 Determination of Monomer to Dimer Ratio of eNOS  
Cell or tissue lysates were prepared as described above in 2.3.1. Samples of equal protein content 
were resuspended in Laemmli Buffer (Table1) and kept for 5 min at room temperature while one 
control sample was boiled to show monomer formation. Samples were then resolved on an 8% 
SDS-Page on ice and at 4°C at 100 V and transferred and probed against total eNOS as described 
under section 2.3.2. 
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2.3.5 Intracellular Cyclic Nucleotide Measurement 
BAEC were starved overnight in endothelial basal medium plus 0.1% BSA prior to treatment. 
Intracellular cGMP levels were determined using an enzyme immunoassay (Amersham, GE 
Health Care, UK) as per the manufacturer’s instructions. Data were normalized to total µg of 
protein with a BCA Assay kit (Pierce Biotechnology, Rockford, IL). 
2.4 ENZYME ACTIVITY 
BAEC were starved overnight in endothelial basal medium plus 0.1% BSA. On the day of 
treatment cells were incubated in assay incubation buffer (10 mmol/L HEPES, 145 mmol/L 
NaCl, 5 mmol/L KCl, 5 mmol/L MgSO4, 10 mmol/L glucose, 1.5 mmol/L CaCl2, 0.25% BSA, 
pH 7.4). Treatment agents were added for 15 min prior to cell stimulation using ACh (10 µM). 
Cells then received [3H]-L-arginine (Perkins Elmer). The assay was terminated 3 min later by the 
addition of stop buffer (5 mmol/L L-arginine, 4 mmol/L EDTA, 4 mmol/L EGTA, 6 mmol/L L-
citrulline in PBS). The cells were lysed with lysis buffer (5 mmol/L Tris-HCl (pH 7.4), 20 
mmol/L EDTA, 0.5% Triton X-100), freeze-thawed twice, and the cell lysate was added to pre-
equilibrated Dowex-50-H+ columns. Equal volumes of eluent were mixed with 5 ml of 
scintillation cocktail, and 3H-citrulline was quantified using a 1900CA Liquid Scintillation 
Analyzer (Packard). Lysate protein levels were determined using a BCA assay, and counts were 
normalized to protein levels. All conditions were assessed in triplicate, and all experiments were 
repeated at least three times. In other experiments cell lysates, prior to running through Dowex 
columns, were counted directly to measure L-arginine uptake.  
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2.5 ANIMAL STUDIES 
2.5.1 Species and Maintenance 
Wildtype C57BL/6, TPS1 null, and CD47 null male mice (Jackson Laboratories) were housed 
under pathogen-free conditions and had ad libitum access to filtered water and standard rat chow. 
All the investigations conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institute of Health (NIH Publications No.85-23, revised 1996), and 
were approved by the IACUC of the University of Pittsburgh and the Animal Care and Use 
Committee of the NCI, NIH. 
2.5.2 Experiments of Vascular Reactivity 
Adult male age matched C57BL/6 wild type, TSP1 and CD47 null or B6129SF2/J mice were 
euthanized by cervical dislocation, the vasculature was gently flushed with warm Krebs buffer 
via puncture of the left ventricle to remove blood and the thoracic and abdominal aorta cleaned 
of surrounding connective tissue in situ and then dissected free. Segments (3 mm in length) were 
mounted in a dual wire myograph system (Multi Myograph Model 610M). Vessels were allowed 
to equilibrate in standard PSS buffer (Table1) supplemented with 0.0031 M meclofenamate 
(cyclooxygenase inhibitor, IC50:0.6 µM, Sigma) and bubbled with 5% CO2, 95% O2 at 37°C. 
Passive tone of the arteries was set to 9.98 mN. Vessels were then allowed to equilibrate until 
baseline tension remained constant (30-60 min). Vessel viability was confirmed by a contractile 
response on addition of KCl buffer (Table1) supplemented with 0.0031 M meclofenamate, 
repeated twice for 5 min each. Concentration-response curves to phenylephrine (PE) were 
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carried out and a dose that produced 80% maximum contraction (EC80) was chosen for 
establishing vascular tone prior to additional treatments. Vessels achieving at least 65% 
relaxation to 10-6 M ACh were considered to have intact endothelium. For treatment with TSP1 
(2.2 nM, Athens Research) vessels were preincubated for 15 min in myograph chamber prior to 
PE constriction and ACh relaxation. For L-NAME (100 µM, Sigma) studies vessels were 
incubated prior to PE constriction for 30min to allow the competitive inhibitor to work. 
2.5.3 Internal Blood Measurement via Telemetry 
Mice were anesthetized using ketamine and xylazine (90 and 10 mg/kg, respectively). The 
telemeter catheter was inserted into the left carotid artery and advanced to reach the aortic arch, 
and the telemeter body (model TA11PA-C20, Data Sciences International, St. Paul, MN) was 
placed in a subcutaneous pocket. The telemeter signal was processed using a model RPC-1 
receiver, a 20-channel data-exchange matrix, APR-1 ambient pressure monitor, and a Dataquest 
ART 2.3 acquisition system (Data Sciences International). The system was programmed to 
acquire data for 10 s every 2 min and to calculate 100 min averages of the mean, systolic, and 
diastolic blood pressure, pulse pressure, heart rate, and activity. Data represent the mean ± SD of 
8 mice of each strain or treatment group. 
2.5.4 Chronic Hypoxic Exposure as Model of PAH 
Age matched male wild type, C57BL/6 and TSP1 null mice were placed in an airtight Plexiglass 
chamber and exposed to 10% O2 for 21days under normobaric conditions. Mice from both 
strains were also maintained in room air and served as normoxic controls (n=8 for all groups). 
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2.5.5 Determination of Ventricular Hypertrophy and Ventricular Pressures 
Mice were anesthetized i.p. with a 1:10 dilution of 1 µl/g body weight pentobarbital (Nembutal, 
sodium solution, 50 mg/ml). Following a tracheotomy mice were ventilated with a tidal volume 
6-8 ml/kg and the thoracic cavity was opened. A calibrated Millar (Millar Instruments Inc, 
Houston, TX) catheter was then inserted into the right ventricle (RV) and RV systolic pressure 
was measured over a 30 sec interval using a PowerLab data acquisition system (AD Instruments, 
Colorado Springs, CO). For ventricular weight measurements, hearts were excised and atria were 
removed. The RV free wall was dissected, and each chamber was weighed. The ratio of RV 
weight to left ventricular (LV) weight plus septum (RV/LV+S) was used as an index of RV 
hypertrophy. 
2.6 HUMAN SAMPLES 
Ten human lung samples from patients not diagnosed with pulmonary hypertension were 
obtained from Joe Pilewski (University of Pittsburgh). Ten human lung samples from patients 
diagnosed with pulmonary hypertension were obtained from Hunter Champion (Johns Hopkins 
University).  
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2.7 HISTOLOGICAL STAINING  
After hemodynamic measurements of the heart mouse lungs were perfused with PBS, fixed for 2 
hrs with 4% paraformaldehyde (PFA at 4°C) and excised. Lungs were transferred into 30% 
sucrose (over night, 4°C), paraffin embedded and sectioned (10 µm). For pulmonary vascular 
morphometry studies images of peripheral arterioles were captured with a Nikon Eclipse 800 
microscope. The diameter of measured vessels ranged between 30-70 µm. Twenty random 
vessels of comparable size per mouse were assessed from 4 mice per group. 
2.7.1 Determination of Nitrotyrosine Formation in the Lung 
Lung sections were de-paraffinized by heating sections for 30 min at 55°C and subsequent 
washes in xylene (2 times for 5 min) and gradual rehydration in ethanol (100% 2 times for 5 min, 
then  95%, 70%, 2 times for 2 min each) followed by one wash in PBS and water. Sections were 
then microwaved in 350 ml sodium citrate buffer for antigen retrieval (2.94 g sodium citrate/L 
pH 6, for 10 min) and allowed to cool for 45 min at room temperature. Sections were blocked 
and stained with a Rabbit anti-Nitrotyrosine antibody (Millipore) in combination with a 
Vectastain ABC kit (Vector laboratories, CA) and a metal enhanced DAB substrate kit (Thermo 
Scientific) following manufacturer’s directions. Sections were counterstained for hematoxylin 
(Vector laboratories, CA), dehydrated in ethanol (70%, 95%, 100% and xylene) and coverslipped 
in mounting medium. 
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2.8 STATISTICS 
All studies were performed a minimum of three independent times and significance was 
determined using the appropriate analysis with Graphpad Prizm software (San Diego, CA). Data 
were analyzed by 1-way ANOVA followed by Tukey test for multiple comparisons. For grouped 
analysis, data were analyzed by 2-way ANOVA followed by Bonferroni post hoc test. 
The arterial reactivity studies were analyzed by performing a nonlinear regression on 
fitted curves. Significance between fitted curves was determined using a two-way ANOVA 
followed by the Bonferroni post test. 
 42 
3.0  THROMBOSPONDIN-1 SUPPORTS BLOOD PRESSURE BY LIMITING 
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3.1 ABSTRACT 
Aims: Thrombospondin-1 (TSP1), via its necessary receptor CD47, inhibits nitric oxide (NO) 
stimulated soluble guanylate cyclase (sGC) activation in vascular smooth muscle cells, and TSP1 
null mice have increased shear-dependent blood flow compared to wild type. However, 
circulating TSP1 is too large to traverse the endothelial basement membrane. These findings 
suggested that endothelial-dependent differences in blood flow in TSP1 null mice may be 
through direct modulation of eNOS activation by circulating TSP1. Herein we test the hypothesis 
that TSP1 inhibits eNOS activation and endothelial-dependent arterial relaxation. 
Methods and Results: Acetylcholine-stimulated activation of eNOS and agonist-driven calcium 
transients in endothelial cells were inhibited by TSP1. TSP1 also inhibited eNOS 
phosphorylation at serine1177. TSP1 treatment of the endothelium of wild type and TSP1 null, but 
not CD47 null arteries, inhibited acetylcholine-stimulated relaxation. TSP1 and CD47 null 
vessels demonstrated greater endothelial-dependent vasorelaxation compared to wild type.  
Conversely, null arteries demonstrated less vasoconstriction to phenylephrine compared to wild 
type, which was corrected by inhibition of eNOS with L-NAME. In TSP1 null mice, intravenous 
TSP1 blocked acetylcholine-stimulated decreases in blood pressure, and both TSP1 and a CD47 
agonist  antibody acutely elevated blood pressure on intravenous administration to mice.  
Conclusions: TSP1, via CD47, inhibits eNOS activation and endothelial-dependent arterial 
relaxation and limits acetylcholine-driven decreases in blood pressure. Conversely, TSP1 and a 
CD47 antibody increase blood pressure. These findings suggest that circulating TSP1, by 
limiting endogenous NO production, functions as a pressor agent supporting blood pressure.  
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3.2 INTRODUCTION 
The vascular endothelium is a critical regulator of blood vessel tone through its production of the 
bioactive gas nitric oxide (NO). NO is generated in the endothelium by the conversion of L-
arginine to L-citrulline catalyzed by the NADPH-dependent enzyme endothelial nitric oxide 
synthase (eNOS), which requires Ca2+/calmodulin, flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), and tetrahydrobiopterin (BH4) as co-factors 72-73. Constitutive 
production of NO by endothelial cells promotes blood flow by inhibiting vascular smooth muscle 
cell (VSMC) contracture and platelet aggregation250. NO-stimulated cGMP synthesis causes 
VSMC relaxation and decreases arterial vascular resistance by stimulating the dephosphorylation 
of myosin light chain-2 251. As such, endothelial NO is a central regulator of vascular health and 
blood pressure. 
Recently we reported that the matricellular protein thrombospondin-1 (TSP1), via its 
necessary receptor CD47, limits NO signaling in vascular cells through inhibiting NO-stimulated 
cGMP production by soluble guanylate cyclase (sGC) 15-17. TSP1 and CD47 null mice show 
increased shear-dependent changes in tissue blood flow and greater decreases in blood pressure 
to an NO challenge compared to wild type animals 12. However, in the absence of disease or 
injury TSP1 is only found as a soluble circulating blood protein and in platelet alpha granules. 
With a mass of 450 kDa, TSP1 is too large to cross the endothelial basement membrane and thus, 
under normal conditions, cannot directly engage the vascular smooth muscle cell layer of 
resistance arteries. Thus it was not clear how circulating TSP1 limited tissue and blood flow 
responses unless it also limited primary eNOS activation and endogenous NO production.  
To test the hypothesis that TSP1 regulates eNOS activation and hence endothelial-
dependent relaxation we studied arterial relaxation in vessels from wild type, TSP1, and CD47 
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null animals. Wild type arteries demonstrated a dose-dependent relaxation to acetylcholine 
(ACh) which was significantly abrogated by pretreatment of the endothelium with physiologic 
concentrations of TSP1. TSP1 and CD47 null arteries demonstrated increased endothelium-
dependent relaxation to acetylcholine compared to wild type arteries which exogenous TSP1 
prevented in TSP1 null vessels only. TSP1 blocked agonist-stimulated eNOS activation and 
modulated calcium transients in endothelial cells. Finally administration of intravenous TSP1 
and a CD47 antibody significantly elevated blood pressure in both wild type and TSP1 null mice. 
These results suggest that circulating TSP1, by limiting eNOS activation and endothelial-
dependent arterial relaxation, functions as a pressor to support arterial tone and blood pressure.  
3.3 RESULTS 
3.3.1 TSP1 limits eNOS activity 
The ability of TSP1 to inhibit NO-stimulated cGMP accumulation and functional responses in 
cultured vascular cells can be explained by CD47-dependent inhibition of the downstream target 
sGC 15-16, 252. Higher basal levels of intracellular cGMP in TSP1 and CD47 null compared to wild 
type vascular endothelial cells 15-16 are also consistent with sGC regulation via CD47, but 
upstream inhibition of eNOS activation could also contribute to these results and has not been 
explored. To examine the ability of TSP1 to regulate basal eNOS activity, endothelial cells were 
treated with TSP1 for 15 min, and eNOS activity was assessed by conversion of [3H]-L-arginine 
to [3H]-L-citrulline (Fig. 4A). TSP1 inhibited basal eNOS activity at concentrations of 0.022 
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nmol/L.  Thus, basal eNOS activity is inhibited by TSP1 concentrations equivalent to normal 
circulating plasma levels 253-254. 
        
 
 
 
Figure 4. TSP1 inhibits basal and agonist-stimulated eNOS activity  
BAEC (5 x 105 cells/well) were serum starved over 24 h and incubated with the indicated amounts of TSP1 (A) or 
TSP1 (2.2 nmol/L) followed by acetylcholine (10 µmol/L) (B) in L-arginine free minimal medium prior to adding 
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[3H]-L-arginine. [3H]-L-citrulline synthesis was determined as described and is presented normalized to total 
protein. Treatments were done in triplicate and repeated three times.  p < 0.05 compared to untreated (A) or ACh 
alone (B). HUVEC (5 x 105 cells/well) were serum starved over 48 h and incubated in serum/additive free medium + 
0.1% BSA and ACh (10 µmol/L) ± TSP1 (2.2 nmol/L). Intracellular cGMP levels were determined using an enzyme 
immunoassay. 
3.3.2 TSP1 blocks eNOS activation by acetylcholine 
Acetylcholine is a physiological activator of eNOS 255-256. Endothelial cells treated with ACh 
demonstrated increased L-citrulline production, and this was blocked by pretreatment with 2.2 
nmol/L TSP1 (Fig. 4B). Acetylcholine stimulates increases in intracellular cGMP in endothelial 
cells 257 and rat aorta 258. TSP1 also completely blocked ACh-stimulated increases in cGMP 
levels (Fig. 4C).  
3.3.3 TSP1-mediated inhibition of eNOS activation does not occur through substrate 
limitation 
Post-translational regulation of eNOS occurs through multiple mechanisms including control of 
its substrates and co-factors 72, 259. To exclude one explanation of the observed inhibition of 
eNOS activation we examined whether TSP1 inhibits the carrier-mediated uptake of L-arginine 
into endothelial cells. Pretreatment of endothelial cells with TSP1 did not significantly inhibit L-
arginine uptake under conditions in which citrulline synthesis was inhibited (data not shown).  
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3.3.4 TSP1 modulates agonist-stimulated calcium transients in endothelial cells and 
murine aortas 
Acetylcholine and ionomycin both activate eNOS in a calcium-dependent manner 260-262. 
HUVEC showed a sustained rise in intracellular calcium in response to ionomycin. However, 
agonist driven calcium transients showed modulation in the plateau phase in cells treated with 
TSP1 compared to control cells (Fig. 5A, B). En face confocal imaging of the endothelium in 
wild type arteries further demonstrated that TSP1 applied to the endothelial layer significantly 
attenuated agonist-driven calcium waves (Fig. 5C). 
A 
 
B 
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Figure 5. TSP1 modulates calcium transients 
HUVEC cells were serum starved in basal medium overnight, loaded with fluo-4-AM and then pretreated 
with/without TSP1 (2.2 nmol/L) followed by stimulation with ionomycin (3 µmol/L). Images were acquired every 3 
sec (20X, 259x259). Data analysis was performed using Pascal 3.2 software (LSM5 Pascal Zeiss) (A) Color Images 
are representative of quantification in (B) (fluorescence intensity bar on right) (B) Analyzed relative changes in 
fluorescence intensity over time (F/F0) as the result of 3 independent experiments. (untreated cells n = 113, TSP1 
treated cells n = 64, +SD) (C) Measurement of the [Ca2+]i flux in situ in fresh aortic segments from wild type mice 
was performed using fluo-4-AM following treatment with/without TSP1 (2.2 nmol/L 15 min) followed by 
ionomycin. Results expressed as the change in area under the curve. Results are the mean ± SD of 6 vessels treated 
with ionomycin and 4 vessels treated with ionomycin + TSP1. p < 0.05 compared to ionomycin alone.  
3.3.5 TSP1 inhibits agonist-stimulated phosphorylation of eNOS 
eNOS activation by ACh and ionomycin is associated with increased phosphorylation at residue 
serine1177 in the human enzyme 263. Treatment of HUVEC with TSP1 blocked both ACh- and 
ionomycin-stimulated eNOS phosphorylation at serine1177 (Fig. 6A, B). Findings in cultured cells 
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paralleled changes in whole vessels. Aortic segments from wild type mice treated with ACh 
showed enhanced eNOS phosphorylation at serine1177 which was blocked by endothelial 
treatment with TSP1 (Fig. 6C).  
3.3.6 TSP1 inhibits agonist-stimulated interactions between eNOS and Hsp90 
Optimal eNOS activation requires specific protein-protein associations. Hsp90 is a chaperone 
protein that associates with eNOS and functions to promote correct folding and activation of the  
enzyme 264. Consistent with its ability to limit eNOS activation and modulate calcium transients 
we found on co-immunoprecipitation that TSP1 inhibited ACh-stimulated association of eNOS 
with Hsp90 (Fig. 6D). 
 
 
 
 51 
  
Figure 6. TSP1 inhibits agonist-stimulated phosphorylation of eNOS 
HUVEC were serum starved over night and pretreated with TSP1 (2.2 nmol/L for15 min) followed by addition of 
ionomycin (3 µmol/L) (A) or ACh (10 µmol/L) for the times indicated (B). Lysates were prepared and Western blot 
analysis of eNOS phosphorylation at serine1177 determined. A representative blot of three experiments for each 
treatment is shown. Arterial segments from wild type mice were pretreated with TSP1 (2.2 nmol/L 15min) followed 
by ACh (10 µmol/L) and lysates blotted against eNOS phosphorylation at serine1177 (C). A representative blot of 3 
separate experiments is presented. HUVEC were serum starved and pretreated with TSP1 (2.2 nmol/L for 15 min) 
followed by ACh (10 µmol/L) for the indicated times. eNOS was immunoprecipitated and then Western blotted 
against Hsp90 and quantitated using Image J (D). A representative blot of 3 separate experiments is presented.  
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3.3.7 Soluble TSP1 inhibits eNOS-dependent arterial relaxation 
To test if soluble TSP1 can inhibit endothelium-dependent relaxation of blood vessels we studied 
ex vivo arterial contraction and relaxation with myography. Arterial relaxation to ACh in wild 
type vessels was inhibited following endothelial treatment with physiologic levels of TSP1 (0.22 
nmol/L) (Fig. 7A) while higher concentrations (2.2 nmol/L) further shifted the response curve to 
ACh and decreased the maximum vasorelaxation response. The signature domain of TSP1, 
E123CaG1, that specifically engages CD47, also inhibited ACh-stimulated vasorelaxation (Fig. 
7B). Thus, luminal TSP1, while not completely preventing eNOS dependent vasodilation by 
ACh, significantly attenuates this response. Ionomycin through activating eNOS also stimulates 
arterial relaxation 265. Since TSP1 modulates ionomycin-stimulated calcium transients in 
endothelial cells and whole arteries, we treated wild type aortic segments with ionomycin. 
Importantly, TSP1 inhibited ionomycin stimulated vasorelaxation (Fig. 7C).   
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Figure 7. TSP1 limits agonist-stimulated vasorelaxation 
Vasorelaxation of pre-contracted aortic segments from wild type male mice was determined in the presence of ACh 
alone. The luminal endothelium of the vessels was then pretreated with exogenous TSP1 (0.22 and 2.2 nmol/L, A) 
or a recombinant domain of TSP1 (E123CaG1, 2.2 nmol/L, B) for 15 minutes and vasorelaxation to ACh 
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determined. Results are the mean ± SD of 16 control vessels, 10 TSP1 (2.2 nmol/L) treated vessels, 6 TSP1 (0.22 
nmol/L) treated vessels and 5 E123CaG1 domain (2.2 nmol/L) treated vessels. p < 0.0001 for both doses of TSP1 
and p < 0.0063 for recombinant domain compared to untreated. Vasorelaxation of pre-contracted aortic segments 
from wild type mice was determined in the presence of ionomycin (3 µmol/L) ± TSP1 (2.2 nmol/L) (C). Results are 
the mean ± SD of 5 vessels per treatment group, p < 0.0008 compared to untreated. All control vessels were set to 
100% relaxation and treated vessels normalized to untreated. All fitted curves were analyzed by two-way ANOVA 
followed by the Bonferroni post test. 
3.3.8 CD47 is necessary for TSP1 inhibition of endothelial dependent vasorelaxation 
eNOS-dependent arterial relaxation is enhanced in TSP1 null vessels compared to wild type  
(Fig. 8A). Conversely, treatment of the endothelial lining of TSP1 null vessels (which express 
CD47) with TSP1 inhibited ACh-stimulated vasorelaxation (Fig. 8B).  However, endothelial-
dependent vasorelaxation to ACh was not inhibited by treating the endothelium of CD47 null 
arteries with TSP1 (Fig. 8C), demonstrating that CD47 is necessary for this process.  
To be certain that these responses in the null vessels are not artifacts resulting from 
differences in eNOS protein, we performed Western analysis of arterial segments and skeletal 
muscle samples from wild type and null mice. No significant differences were found in eNOS 
protein levels in arterial segments or skeletal muscle biopsies (Fig. 8D). Increased 
responsiveness in null vessels to ACh could also arise from increased sGC protein. However, no 
difference in sGC protein levels were found by Western blotting of lung tissue (Fig. 8E) or 
skeletal muscle samples (data not shown) from null mice as compared to wild type.  
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Figure 8. Inhibition of endothelial-dependent arterial relaxation by TSP1 requires CD47 
Vasorelaxation dose-response curves of wild type and TSP1 null were determined to ACh (A).  Data represent the 
mean ± SD of 6 TSP1 null and 4 control vessels. p < 0.001 TSP1 null compared to wild type on two-way ANOVA 
and Bonferroni post test. Vasorelaxation to ACh was determined in TSP1 (B) and CD47 null (C) aortic segments 
before and after treatment of the luminal endothelium with soluble TSP1 (2.2 nmol/L). Data represent the mean ± 
SD of 4 TSP1 null and 5 CD47 null mice. Two-way ANOVA analysis and Bonferroni post test of the significance of 
TSP1 treatment of TSP1 null arteries on ACh-stimulated vasorelaxation showed p < 0.0028 compared to untreated 
TSP1 null arteries. Lysates from thoracic aortic segments (n = 3 vessels per strain) and vastus medialis muscle 
biopsies from age and sex matched wild type and null mice were probed by Western analysis for total eNOS and 
quantified using Image J (D). For each tissue type representative blots of three experiments are presented.  Lung 
tissue from age and sex matched wild type, TSP1 and CD47 null mice was processed for Western analysis of sGC 
subunits α1 and β1 (E). A representative blot of three experiments is presented.  
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3.3.9 TSP1 potentiates arterial vasoconstriction 
Arterial tone represents a balance between vasorelaxation and vasoconstriction 266. Consistent 
with their enhanced endothelial-dependent vasorelaxation, TSP1 and CD47 null arteries 
demonstrated decreased vasoconstriction to phenylephrine compared to wild type vessels (Fig. 
9A, B). Inhibition of eNOS with L-NAME corrected the resistance to phenylephrine-stimulated 
vasoconstriction in TSP1 null arteries (Fig. 9C),   providing additional evidence for increased 
eNOS activity in null vessels and confirming ex vivo our in vivo findings of enhanced shear-
dependent perfusion in TSP1 null mice that was eliminated with L-NAME 12. Consistent with the 
ability of TSP1 to limit eNOS-dependent vasorelaxation, treatment of the endothelium of wild 
type arteries with TSP1 more than doubled the vasoconstriction induced by phenylephrine (Fig. 
9D) a response that was mimicked by the CD47-binding domain of TSP1, E123CaG1 (Fig. 9E). 
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Figure 9. TSP1 potentiates phenylephrine-stimulated vasoconstriction 
Vasoconstriction to PE to was determined in wild type and TSP1 null arteries (A) or wild type and CD47 null 
arteries (B). Data represent the mean ± SD of 8 vessels from each strain (A) and 12 vessels from each strain (B). 
Two-way ANOVA analysis and Bonferroni post test of significance of PE-stimulated vasoconstriction in wild type 
versus TSP1 and CD47 null arteries showed p < 0.0001. Vasoconstriction to PE ± L-NAME (100 µmol/L) was 
determined in wild type and TSP1 null arteries (C). Data represents the mean ± SD of 5 vessels of each strain. Two-
way ANOVA analysis and Bonferroni post test of significance of PE-stimulated vasoconstriction in wild type versus 
TSP1 null vessels showed p < 0.0001 compared to no difference in significance in vasoconstriction in wild type and 
null vessels treated with PE + L-NAME. Vasoconstriction of wild type arteries was determined in response to an 
EC80 dose of PE ± TSP1 (2.2 nmol/L) (D) or a recombinant fragment of the signature domain of TSP1 (E123CaG1, 
2.2 nmol/L) (E). Data represent the mean ± SD of 4 vessels in each treatment group.  p < 0.05 compared to PE alone 
(D, E).  
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3.3.10 Circulating TSP1 limits acetylcholine-stimulated changes in mean arterial pressure 
To assess the in vivo role of circulating TSP1 in regulating eNOS-dependent vasorelaxation and 
blood pressure, age matched male wild type and TSP1 null mice bearing telemetric pressure 
transducers were treated with ACh (0.08 µg/gram weight i.v.) and mean arterial pressure (MAP) 
measured (Fig. 10A). TSP1 null mice demonstrated a significant decrease in MAP following 
ACh treatment. A similar dose of ACh in wild type animals did not result in a significant change 
in MAP, suggesting that circulating levels of TSP1 in the blood are sufficient to limit eNOS 
activation by ACh. The administered dose of ACh minimally altered heart rate in either strain of 
animals (data not shown), suggesting that the hypotensive effects demonstrated in TSP1 null 
animals were due to endothelial-dependent vasorelaxation and not secondary to acetylcholine-
stimulated bradychardia. Importantly, pre-treating TSP1 null mice with intravenous TSP1 (11 
pmol/L/gram weight), which was previously shown to significantly elevate circulating plasma 
TSP1 levels for over 6 h 267, blocked the ACh-stimulated decrease in blood pressure 
recapitulating the wild type response in null mice (Fig. 10B).  
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Figure 10. Circulating TSP1 limits endothelial dependent changes in blood pressure and is a 
hypertensive on acute administration 
Age matched male wild type and TSP1 null mice bearing telemetric pressure transducers were treated with i.v. ACh 
(0.08 µg/gram weight) and MAP (A) determined. TSP1 null mice were pretreated with intravenous TSP1 (11 
pmol/L/gram body weight) and followed 3 hrs later by i.v. ACh challenge and MAP determined (B). Age matched 
male wild type and TSP1 null mice were treated with intravenous TSP1 (22 pmol/L/gram body weight) and MAP 
determined via telemetry transducer (C). Results represent the mean ± SD over a 2 h time interval post-
administration of 4 animals of each strain. p < 0.05 compared to untreated. Age matched wild type and TSP1 null 
male mice received a CD47 antibody (clone 301, 4 µg/gram weight) or vehicle (normal saline) and the change in 
MAP and diastolic blood pressure determined via telemetric transducer (D, E). Results represent the mean ± SD 
over a 2 h time interval post-administration of 8 animals of each strain (exp. in this figure were performed by Dr. 
Isenberg).  
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3.3.11 Systemic administration of TSP1 increases blood pressure in mice 
Circulating levels of TSP1 have been found to be significantly elevated in several conditions 
associated with decreased tissue blood flow and elevated blood pressure including type I diabetes 
268, dermatomyositis 269, systemic sclerosis 270 and sickle cell disease 271.  We treated telemetric 
transducer bearing wild type and TSP1 null mice with intravenous TSP1 (22 pmol/L/gram body 
weight) and followed blood pressure for 2 h. Consistent with its inhibition of endothelial-
dependent vasorelaxation and enhancement of phenylephrine-stimulated vasoconstriction, 
intravenous TSP1 elevated MAP in wild type and TSP1 null mice (p < 0.05, Fig. 10C).  
3.3.12 A CD47 antibody alters blood pressure in wild type and TSP1 null mice 
To further explore the role of TSP1-CD47 signaling on blood pressure we studied the acute 
effects of a CD47 targeting monoclonal antibody on blood pressure. Wild type and TSP1 null 
mice were treated with CD47 antibody (clone 301) and blood pressure measured via telemetric 
transducer. Mimicking intravenous TSP1, engagement of CD47 with this antibody increased 
mean and diastolic blood pressure significantly in TSP1 null mice and mean arterial pressure in 
wild type mice (Fig. 10D, E). An isotype-matched control antibody did not change blood 
pressure (data not shown).  
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3.4 DISCUSSION 
TSP1, via its receptor CD47, limits NO signaling in isolated endothelial cells, VSMC, and 
platelets by inhibiting NO-stimulated cGMP production by soluble guanylate cyclase 15-17. Based 
on its mass of 450 kDa, TSP1 is unable to cross the subendothelial basement membrane in 
normal physiologic states. Therefore, circulating TSP1 cannot directly influence VSMC 
NO/cGMP signaling in intact vessels and yet TSP1 and CD47 null mice demonstrate enhanced 
shear-dependent changes in blood flow. We demonstrate herein that circulating TSP1 in vivo 
blocks endothelial-dependent decreases in blood pressure. Equally significant, intravenous TSP1 
elevates blood pressure. This can be explained by our finding that TSP1-CD47 signaling inhibits 
eNOS activation in endothelial cells. Thus, TSP1 limits production of the diffusible vasodilator 
NO. This mechanism is consistent with our observations that addition of TSP1 to the luminal 
compartment in wild type and TSP1 null, but not in CD47 null arteries, decreases ACh-
stimulated vasodilation. Further, treatment of the endothelium of wild type arterial segments with 
TSP1, and a recombinant domain of TSP1 that binds to CD47, by limiting NO production, 
potentiates phenylephrine-stimulated vasoconstriction.  
In endothelial cells, TSP1 inhibits basal eNOS function as well as ACh-stimulated eNOS 
activation as measured by L-citrulline production. Importantly from a physiologic perspective 
exceedingly low levels of TSP1 (0.022 nmol/L) inhibited eNOS indicating that circulating levels 
of TSP1 are sufficient to limit both background and activated eNOS production of NO. 
Acetylcholine and ionomycin stimulation of endothelial cells is associated with activation of the 
PLC-IP3 pathway, leading to Ca2+-dependent eNOS activation and NO production 272-274. TSP1 
modulates Ca2+ transients in endothelial cells and blocks phosphorylation of eNOS at serine1177. 
Thus,TSP1 modifies eNOS activity and endogenous NO production through altering cellular 
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calcium signaling, protein phosphorylation and protein-protein association. Acetylcholine 
interacts with M1 and M3 receptors on endothelial cells and through the heterotrimeric protein 
Gαq elevates IP3 and intracellular Ca2+ 46. CD47 in complex with several integrins is believed to 
function as an atypical G-coupled protein receptor 31 In endothelial cells a CD47 antibody that 
blocked neutrophil activation also inhibited fibronectin-stimulated changes in cellular calcium 
275. Expanding upon these findings, our results support a novel role for TSP1 in regulating 
calcium in endothelial cells. 
 Interestingly inhibited Ca2+ transients in endothelial cells stimulated by ionomycin, but 
ionomycin does not act merely as a simple ionophore at the plasma membrane 276. Rather, 
ionomycin also increases Ca2+ release from internal stores.  Furthermore, thrombin has been 
shown to inhibit ionomycin-stimulated flux in HUVEC 277, indicating that physiological 
inhibition of this flux is possible.   
Shear stress also induces a primary Ca2+ flux in endothelial cells and eNOS activation 278 
and calcium signaling changes in isolated vascular cells are known to differ from changes in 
endothelium response in intact vessels279.  En face analysis of arterial segments demonstrated 
that exogenous TSP1, on engaging the luminal endothelium, attenuated agonist-induced calcium 
waves on the intact endothelium. Recently pro-atherogenic turbulent flow conditions were linked 
to increased TSP1 expression 280. Increased TSP1 under such conditions may account in part for 
the decreased NO bioavailability found in atherosclerotic arteries through modulating local Ca2+ 
transients in endothelial cells and secondary eNOS activation. 
Blood pressure is determined by several factors including arterial tone 281-282. NO is 
produced at low physiologic levels by the vascular endothelium at all times. Blockade of NO 
production using the NOS inhibitor L-NAME leads to hypertension in animals and people 283-284. 
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Hypertension in eNOS null mice, has been associated with increased TSP1 expression 285. 
Conversely a recent clinical series noted an association between patients with hypotension and 
abnormally low levels of circulating TSP1 286. Consistent with the ability of circulating TSP1 to 
inhibit eNOS activation and endothelial-dependent vasorelaxation, TSP1 null animals treated 
with ACh demonstrated a significant decrease in MAP compared to wild type mice.  Intravenous 
replacement of TSP1 in null mice blocked the ACh-stimulated drop in blood pressure, and in 
wild type and null mice intravenous TSP1 and a CD47 antibody elevated blood pressure. These 
new results explain in part published findings that TSP1 null mice demonstrate a greater decrease 
in MAP after partial sympathetic blockade compared to wild type mice 18. Taken together, the 
results presented herein suggest that circulating TSP1 provides a rheostat to limit eNOS 
activation and NO production and in doing so exerts a pressor activity upon blood pressure. 
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4.1 ABSTRACT 
Pulmonary hypertension (PH) is a fatal lung disease characterized by pulmonary vascular 
remodeling leading to increased pulmonary vascular resistance and right heart failure.  
Endothelial dysfunction is described as an initiating event leading to PH. Recently, 
thrombospondin-1 (TSP1) was reported to inhibit NO signaling by preventing activation of 
soluble guanylate cyclase and cGMP-dependent protein kinase. We thus hypothesized that TSP1 
plays an important role in the pathogenesis of PH. Increased TSP1 expression was noted in 
humans with PH and corresponded to dysregulation of eNOS. In a mouse model of PH, TSP1-/- 
mice displayed minimal increases in right ventricular pressure and hypertrophy and decreased 
evidence of muscularized arterioles compared to WT mice. Under normoxic conditions eNOS 
phosphorylation was increased in lungs from TSP1-/- mice. Following hypoxia eNOS 
phosphorylation remained unchanged in WT lungs and was decreased in TSP1-/- lungs. Akt 
phosphorylation was significantly increased in WT hypoxic lungs but not TSP1-/- lungs. 
Alternatively, TSP-1 null hypoxic lungs exhibited a doubling of caveolin-1 expression. eNOS 
monomer was increased in WT and TSP1-/- hypoxic lungs but only WT mice showed evidence 
of increased oxidative stress.  This suggests that these conditions, leading to suppression of 
eNOS activity in the TSP1-/- hypoxic lungs, may be protective.  This hypothesis is supported by 
recent studies implicating overactive eNOS as the cause of PH in caveolin-1 null mice. These 
findings imply a dual role for TSP1 in PH. Initially, by suppressing eNOS activation and NO 
signaling, and later by promoting eNOS-derived reactive oxygen species.  
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4.2 INTRODUCTION 
Pulmonary hypertension (PH) is a disease of the small pulmonary arteries marked by a 
progressive increase in pulmonary vascular resistance leading to uncompensated right heart 
failure and ultimately death 188, 193, 200.  While idiopathic PH occurs in the absence of any known 
insult, secondary PH results from chronic obstructive or interstitial lung diseases, scleroderma, 
heart disease, sleep apnea, and sickle cell disease 195, 287. Independent of its etiology PH is 
characterized by remodeling of the pulmonary vasculature, vasoconstriction, and thrombosis in 
situ 193.  
One of the key initiating events leading to PH is endothelial dysfunction characterized by 
uncoupling of endothelial nitric oxide synthase and an associated lack of bioavailable nitric 
oxide (NO) 288-290.  NO plays an important role in vascular homeostasis by causing vasodilation 
291-292 and by suppressing VSMC proliferation 293-294, inflammation 295 and subsequent vascular 
remodeling. Thus it is not surprising that eNOS null mice are more susceptible to the 
development of PH.  Regulation of eNOS activity is complex depending on phosphorylation, 
protein-protein interactions, and localization to specialized areas of the cell membrane. The 
serine threonine kinase Akt phosphorylates eNOS leading to its activation whereas Caveolin-1 
(Cav-1) limits eNOS activity via direct association. Disassociation or loss of Cav-1 leads to 
enhanced eNOS activity and increased NO production. Paradoxically, Cav-1 null mice 
spontaneously develop pulmonary hypertension which is ameliorated by re-expression of 
caveolin-1 in the endothelium or eNOS inhibition. 
Recent work by this group has found that the matrix cellular protein thrombospondin-1 
(TSP1), through binding its receptor CD47, blocks physiologic NO responses in vascular cells 16-
17. Primary lung vascular cells from TSP1 and CD47 null mice demonstrate elevated levels of 
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cGMP indicating that endogenous TSP1 constantly limits NO/cGMP signaling. Additionally we 
have previously shown that TSP1 directly inhibits activation of soluble guanylate cyclase (sGC), 
thus cGMP production as well as activity of cGMP-dependent protein kinase 15-17. Importantly, 
targeting TSP1 will maximize physiologic NO signaling, increase tissue perfusion and blood 
flow while minimizing inflammation and thrombosis 252, 296-298.  Thus its inhibition may offer 
therapeutic benefits in vascular disease.  
We, therefore, hypothesized that TSP1 contributes to the development of PH in humans 
and that the lack of TSP1 in null mice is protective in a PH model of chronic hypoxia. 
Interestingly, we observed a marked increase in TSP1 expression in a cohort of patients 
diagnosed with primary and secondary PH. These findings in human PH were recapitulated in 
wild type mice with hypoxia-induced PH. Importantly, TSP1-null mice were significantly 
protected from the development of PH in this model in part through a decrease in 
oxidative/nitrosative stress and concurrent suppression of uncoupled eNOS activity.  
4.3 RESULTS 
4.3.1 TSP1 expression is increased in primary and secondary pulmonary hypertension 
Several reports suggest that TSP1 expression is increased in cardiovascular disease 299-300. 
However, there are no data on the role of TSP1 in pulmonary hypertension. Fig 11A shows a 
representative Western blot of lung specimens from non-PH patients, scleroderma-associated PH 
patients (SCD), and patients with iodpathic PH (IPAH). Densitometry of Western blots from the 
total cohort of 10 non-PH patients, and 10 PH patients (5 SCD and 5 IPAH) reveals a significant 
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increase in TSP1 protein expression in both SCD and IPAH compared to samples from patients 
without PH.  
 
Figure 11. TSP1 expression is increased in patients with pulmonary hypertension. 
(A)  Lung tissue from non-PH, idiopathic PH or scleroderma associated PH patients was probed by Western blot for 
TSP1 and β-actin. Western blot is only representative. Densitometry below is the result of 10 non-PH patients, 5 
SCD patients, 5 IPAH patients and is presented as mean ratio of TSP1 to β-actin (± S.D). * = statistically significant 
(p < 0.05) compared to non PH patients. (B) Representative Western blot of lung tissue from normoxic and chronic 
hypoxic WT and TSP1 null mice probed against TSP1 and β-actin. Densitometry is presented as mean ratio of TSP1 
to β-actin  (± S.D) * = statistically significant (p < 0.05) compared to normoxic mice and is based on analysis of 4 
mice per group. 
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4.3.2 TSP1 exacerbates cardiovascular hemodynamics in hypoxia-driven PH 
Based on the findings in the human patient samples we wished to determine whether TSP1 plays 
a role in the development of PH.  In order to induce PH, WT or TSP1 null mice were subjected 
to three weeks chronic hypoxia (FIO2 = 0.10) with animals maintained in room air serving as 
controls.  As with the human patient population, induction of  pulmonary hypertension in WT 
mice led to significantly increased TSP1 expression compared to normoxic controls (Fig 11B).  
There was no difference in baseline RV pressures or hypertrophy in WT vs. TSP1-/- mice 
(Fig 12A, 12B). As expected chronic hypoxia led to a significant rise in RV pressure with 
associated RV hypertrophy in WT mice (n=8). However, after chronic hypoxia the loss of TSP 
significantly attenuated the rise in RV pressure and RV hypertrophy compared to WT animals. 
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 Figure 12. Loss of TSP1 protects mice from hypoxia-induced PH 
WT type and TSP1 null mice were exposed to 21 days chronic hypoxia or room air.  At the end of the exposure 
period, (A) right ventricular systolic pressure, and (B) right ventricular hypertrophy (Fulton Index) were determined.  
Data represent mean ± S.D. (n = 8 per group).  *=statistical significance (p<0.05) compared to WT hypoxic. 
4.3.3 TSP1 null lungs demonstrate decreased numbers of hypertrophied arterioles 
following chronic hypoxic challenge 
A histological hall mark of pulmonary hypertension is vascular remodeling manifested as the 
increased presence of muscularized arterioles in the lung parenchyma 188. Histological analysis 
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of tissue sections of lungs from wild type (n=4) and TSP1 null mice (n=4) subjected to 3 weeks 
of hypoxia was performed by an observer blinded to the genetic background of the tissue.  Fig. 
13B shows a representative image of H&E stained pulmonary arterioles from each treatment 
group. Sections of TSP1 null lungs demonstrated significantly fewer muscularized arterioles 
compared to lungs from wild type mice. Quantitation was based on 20 randomly picked 
arterioles per mouse (Fig. 13 A). 
 
Figure 13. TSP1 null mice exhibit less arteriolar muscularization after chronic hypoxic exposure 
(A) Representative images of H&E stained pulmonary arterioles from normoxic and hypoxic WT and and TSP1 null 
mice.  Scale bar represents 50μm. (B) Sections of lungs were analyzed for muscularization of arterioles by a blinded 
observer. TSP null mice exposed to chronic hypoxia showed less muscularization than WT mice exposed to chronic 
hypoxia (n = 4 mice per group, analysis is the result of 20 vessels per section).  * = statistical significance (p<0.05) 
compared to corresponding normoxic control. 
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4.3.4  eNOS phosphorylation is altered in lungs of TSP1 null mice exposed to chronic 
hypoxia 
Fig. 14A shows a representative Western blot of WT and TSP1 null mice exposed to normoxia 
or hypoxia probed against, eNOS, phospho-serine 1176 eNOS or β-actin. Densitometry of 
protein expression was based on 4 mice per group. As previously reported, WT mice 
demonstrated a significant increase in total eNOS protein expression when exposed to chronic 
hypoxia, which was also observed in TSP-1 null mice (Fig 14B).  
Maximum endothelial nitric oxide synthase (eNOS) activity and NO production are 
associated with phosphorylation of eNOS at serine 1176 (serine 1177 in human). WT mice 
exposed to hypoxia showed no change in eNOS phosphorylation compared to WT normoxic 
mice (Fig. 14C). Interestingly, lungs of normoxic TSP1 null mice demonstrated a significant 
increase in eNOS phosphorylation compared to normoxic WT mice (Fig. 14C) suggesting that 
TSP1 limits eNOS activity under normal physiology. In contrast, TSP1 null mice exposed to 
chronic hypoxia displayed a significant decrease in the ratio of phospho- to total eNOS compared 
to both WT and TSP1 null normoxic mice (Fig. 14C).  
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 Figure 14. TSP1 changes eNOS regulation in hypoxic pulmonary hypertension 
(A)  Representative Western blot of lung tissue from WT and TSP1 null mice exposed to hypoxia or room air 
probed against total eNOS protein, eNOS phosphorylation at serine-1177, and β-actin. (B) Densitometry is based on 
4 mice per group presented as mean ratio of total eNOS to β-actin  (± S.D) (C) Densitometry is based on 4 mice per 
group presented as mean ratio of phosphorylation at Ser1177 to total eNOS ( ± S.D) * = statistically significant 
increase compared to WT normoxic (p < 0.05).  # = statistically significant decrease compared to WT normoxic (p < 
0.05). 
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4.3.5 Hypoxia-driven ROS is decreased in the absence of TSP1 
Oxidative stress is known to contribute substantially to chronic vasculopathy including 
pulmonary hypertension. One source of oxidative stress in the blood vessel wall is uncoupled 
eNOS characterized by a loss of eNOS dimer (and a concomitant increase in monomer). 
Interestingly, both wild type and TSP1 null lungs showed a rise in eNOS monomer to dimer ratio 
after hypoxic challenge as shown in the representative native Western blot (Fig. 15A). 
Densitometry was based on 4 animals per group and showed a significant increase in eNOS 
monomer to dimer ratio in both WT and TSP1 null hypoxic lungs (Fig. 15B).  
Nitrotyrosine is a common marker of oxidative and nitrosative stress such as that 
produced by uncoupled eNOS.  Immunostaining of normoxic and hypoxic WT or TSP1 null 
mice revealed increased nitrotyrosine staining in the lungs of hypoxic WT mice (Fig 15C).  In 
contrast, nitrotyrosine staining was unchanged in hypoxic TSP1 null mice compared to normoxic 
WT or TSP1 null animals.  
 
 
 
 
. 
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Figure 15. Loss of TSP1 prevents increased ROS production in hypoxic pulmonary hypertension 
(A) Representative native gel electrophoresis probed against eNOS to determine eNOS monomer to dimer ratio in 
WT and TSP1 null mice after chronic hypoxia or room air. (B) Densitometry is presented as  monomer to dimer 
ratio of eNOS expression ± S.D. (n = 4). (C) Representative photomicrographs of lung tissue from WT and TSP1 
null mice exposed to chronic hypoxia or room air stained using antibodies against nitrotyrosine.  Staining was 
performed on 2 sections from 4 mice in each group.  Scale bar represents 100 μm. 
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4.3.6 TSP1 promotes Akt activation in hypoxic pulmonary hypertension 
Activation of  Akt drives eNOS activation in endothelial cells via phosphorylation of s1176 on 
eNOS . Also, Akt activation promotes the proliferation of  vascular smooth muscle cells and thus 
contributes to vascular remodeling. Following chronic hypoxia total Akt expression was 
unchanged in wild type and TSP1 null lungs (Fig. 16A, B). Importantly, Akt phosphorylation 
was dramatically increased in wild type lungs (Fig. 16A, C). In contrast, TSP1 lung mice showed 
no change in Akt phosphorylation after hypoxic challenge.  Densitometry was based on 4 
animals per group.  These data are consistent with both the observed changes in eNOS 
phosphorylation and histological evidence of decreased arterial muscularization in hypoxic TSP1 
null lungs. 
 
Figure 16. Effects of TSP1 on eNOS regulatory proteins in PH  
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(A)  Representative Western blots of lung tissue from WT and TSP1 null mice exposed to chronic hypoxia or room 
air probed for AKT, phospho-serine 473 Akt, caveolin-1. and β-actin. (B -D) Densitometry is presented as ratio of 
(B) total AKT expression compared to β-actin (mean ± S.D. n = 4). and (C) phospho-AKT to total AKT( mean ± 
S.D. n = 4). (D) Densitometry presents ratio of caveolin-1 to β-actin expression ± S.D. (n = 4). * = statistically 
significant (p < 0.05) compared to WT normoxic. 
4.3.7 Hypoxic TSP1 null mice show increased pulmonary Caveolin-1 expression 
Besides phosphorylation, eNOS activity is also regulated through key protein-protein 
interactions 91, 97.  Caveolin-1 (Cav-1) binds to and inhibits eNOS and its expression is inversely 
related to eNOS activity. Recent data further demonstrate a role for caveolin-1 in limiting PH. 
Western blot reveals that lungs from TSP1 null mice express more Cav-1 protein after chronic 
hypoxia, whereas cav-1 expression remains unchanged in hypoxic wild type lungs (n=4 mice per 
group, Fig 16 A, D). 
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 Figure 17. eNOS and AKT dysregulation in patients with PH 
(A)  Representative Western blots of lung tissue from non-PH, idiopathic PH or scleroderma associated PH patients 
probed for eNOS phosphoserine-1177 eNOS, Akt, phospho-Akt, caveolin-1 and β-Actin. (B-E) Quantitation of 
densitometric analysis of (B) mean ratio p-eNOS to total eNOS, (C) mean ratio of p-Akt to total Akt, (D) mean ratio 
of caveolin-1 to β-Actin, and mean ratio of eNOS monomer to eNOS dimer. All ratios represent mean ± S.D. and 
are the result of  the total cohort (10 non-PH patients and 10 PH patients (5 idiopathic and 5 scleroderma PH). * = 
statistically significant (p < 0.05) compared to non-PH patients. 
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Hyperactive eNOS and AKT contribute to human pulmonary hypertension 
Recent studies demonstrate that hyperactive eNOS may contribute to pulmonary hypertension. 
Consistent with this hypothesis, lung samples from patients with pulmonary hypertension 
demonstrated evidence of increased eNOS and Akt activation as shown by Western blot (Fig 
17A-C).   Additionally, eNOS monomer to dimer ratio was increased in samples from PH 
patients suggesting eNOS uncoupling (Fig 17A, D). These data were consistent with data from 
chronically hypoxic mice. Interestingly, in contrast to our findings in WT hypoxic mice we 
observed increased expression of Cav-1 in lung samples from patients with PH (Fig. 17 A, E). 
Densitrometric analysis of eNOS, Akt, and caveolin-1 expression was based on the total cohort 
of 10 non-PH patients and 10 PH patients (5=SCD, 5= IDAP). 
4.4 DISCUSSION 
The rationale for this study was based on two observations: 1) endothelial dysfunction is a key 
initiator of PH and 2) TSP1 inhibits the canonical NO pathway.  We have shown previously that 
TSP1 in vascular cells can modulate normal vessel wall function and others have shown that 
increased TSP1 expression in hypoxia is linked to endothelial cell apoptosis and VSMC 
migration and proliferation. We show here for the first time that TSP1 expression is significantly 
elevated in a cohort of PH patients compared to non-PH patients. Interestingly, this increase was 
not just observed in patients diagnosed with idiopathic PH, but also in patients diagnosed with 
secondary PH. The mouse model of hypoxia-induced PH recapitulated our findings observed in 
patients by demonstrating a significant increase in TSP1 expression in WT hypoxic mice.  
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Importantly, the TSP1 null mice were protected from hypoxia-induced pulmonary hypertension. 
Compared to WT mice TSP1 null animals displayed significantly reduced RV systolic pressure 
and RV hypertrophy in conjunction with less hypertrophy of  pulmonary arterioles. Since the 
lack of TSP1 shows protection from PH, our findings suggest that TSP1 exacerbates the 
development of the disease.  
In order to gain mechanistic insight into the role of TSP1 in PH we explored the role of 
TSP1 in regard to eNOS. Under normoxic conditions, TSP1 null mice exhibited a substantial 
increase in eNOS phosphorylation at serine 1176 compared to WT mice.  This increase in eNOS 
phosphorylation, and presumably activity, could be one mechanism by which the loss of TSP1 
limits PH.  These data also suggest that physiologic levels of TSP1 constantly limit eNOS 
activity in vivo.  In the setting of hypoxia total NOS expression was increased two-fold in WT 
and TSP1 null animals. While we observed no increase in the ratio of phospho-eNOS to total 
eNOS in the WT hypoxic lungs compared to normoxia, the overall upregulation of eNOS 
suggests an increase in the total amount of active eNOS under hypoxia. In contrast, the ratio of 
phospho-s1176 eNOS to total eNOS was significantly decreased in hypoxic TSP1 null mice 
suggesting decreased eNOS activity in hypoxia. The difference in eNOS phosphorylation 
between these groups was likely due, in part, to increased expression of caveolin-1 in the TSP1 
null hypoxic mice.  These findings are relevant in light of recent reports that overactive eNOS, in 
the setting of caveolin-1 null mice, contributes to hypoxia-induced PH. In these studies, 
overactive eNOS was associated with increased ROS production in the lungs of the caveolin-1 
null mice, which was suggested to occur in response to uncoupled eNOS.    
In our experiments, hypoxia uniformly increased eNOS monomer in both wild type and 
TSP1 null mice. However, in contrast to wild type animals, null mice showed less evidence of 
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ROS in tissues consistent with a lack of superoxide production from uncoupled eNOS. Based on 
this current work and those demonstrating a protective role for cav-1 in PH, it is reasonable to 
speculate that TSP1 null mice enjoy tissue protection in part through the inhibition of uncoupled 
eNOS activity as a result of increased caveolin-1 expression.   
The lack of increased phosphorylation of Akt in hypoxic TSP1 null mice compared to 
wild type mice correlates with several observations in this study. Firstly, Akt is known to 
phosphorylate eNOS on serine 1177 and the pattern of Akt phosphorylation closely resembles 
that of eNOS in this study.  This suggests that, in addition to changes in Cav-1 expression, 
differences in Akt phosphorylation likely contribute to the differences seen in eNOS 
phosphorylation.  Also, Akt is indirectly activated by ROS and thus the lack of Akt 
phosphorylation in the TSP1 null hypoxic mice correlates with decreased evidence of ROS in 
these mice.  Finally, the Akt signaling pathway promotes vascular smooth muscle cell growth 
and survival and thus decreased Akt activation in the hypoxic TSP1 null mice is consistent with 
the observed decrease in vascular hypertrophy. 
Similar to changes seen in hypoxic vs. normoxic WT mice, samples from PH patients 
exhibited both increased Akt and eNOS phosphorylation compared to non-PH samples.  This 
suggests some similarity in mechanism between mouse and man.  Interestingly, while we 
observed no change in caveolin-1 in WT hypoxic mice, samples from PH patients showed 
increased caveolin-1 expression.  This differs dramatically from a recently published work that 
reported decreased caveolin-1 expression in both hypoxic WT mice and a cohort of 4 samples 
from PH patients. In mice, this discrepancy could be due to strain differences since the caveolin-
1 null mice are on a mixed background compared to the TSP1 null mice which are on a C57Bl6/J 
background.  In terms of the difference observed in human samples one can only speculate that 
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this may be due to differences in the stage of disease or perhaps in sample handling.  However, 
as in TSP1 null mice, we would hypothesize that the upregulation of caveolin-1 in our human PH 
samples could be a potential protective mechanism since we observed a substantial increase in 
eNOS uncoupling in these same samples.  
Taken together, the findings presented in this study suggest that TSP1 has a dual role in 
promoting hypoxia-driven PAH. Initially, by suppressing eNOS activation and later by 
promoting conditions leading to increased ROS. Targeting TSP1, resulting in enhancement of 
endogenous NO production and signaling and suppression of VSMC proliferation, may thus 
represent a novel therapeutic strategy for treating pulmonary hypertension.  
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5.0  CONCLUSIONS 
5.1 TSP1 AND PULMONARY DISEASE 
Pulmonary hypertension, a disease characterized by increased pulmonary pressures, is affecting 
an increasing number of people nationwide. There is no known cure for PH and the mortality 
rate remains high. While primary PH (familial or idiopathic) seems unpreventable at this point, 
secondary PH results from the progression of, among other diseases, interstitial lung disease, 
autoimmune disease, or portal hypertension. In the case of secondary PH the disease may arise 
from preventable causes.  For example COPD and interstitial lung disease, has been attributed to 
environmental risk factors, including smoking, obesity, and/or air pollution.    
The overall vasoconstrictive phenotype in the lung results from vascular remodeling 
leading to occlussion and thus hypoxic areas in the pulmonary microvasculature, elevated 
expression of vasoconstrictors, a decrease in vasodilatory molecules, and increased 
inflammation. 
This dissertation presents evidence demonstrating that the soluble protein TSP1 exerts a 
continuously constrictive influence on the vasculature and thus blood pressure. Additionally, 
TSP1 levels are significantly elevated in patients suffering from PH leading to further 
aggravation of the disease. The data indicate that the lack of TSP1 significantly protects mice 
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from developing hypoxia-induce PH, as shown by vastly improved hemodynamics and decreased 
right ventricular and vascular hypertrophy.  
It was previously shown by our group that TSP1 leads to direct inhibition of cGMP 
production, and thus negatively regulates the NO-mediated vasodilatory pathway. We show in 
this study that one mechanism by which TSP1 exerts its vasoconstrictive effect is due to direct 
inhibition of eNOS. These data suggest that therapies that target eNOS/NO pathway may be 
limited by the presence of endogenous TSP1. Thus, these discoveries may lead to better drug 
development that focus on TSP1, its necessary interaction with CD47, and its downstream 
inhibitory effect on eNOS.  
5.2 TSP1 - A NOVEL DAMPER OF NO 
Proper function of eNOS is critical in maintaining blood pressure. Its dilatory role in physiology 
has been well established and studied over the last two decades. It also is not surprising that 
acute release of constrictive agents shifts the balance established by eNOS towards hypertension. 
However, here we show that thrombospondin-1 which is endogenously and constitutively 
expressed as soluble protein in the blood, dampens the dilatory effect of eNOS under healthy 
steady state conditions.  
It was previously shown by our group that addition of TSP1 to vascular cells, via its 
necessary interaction with the receptor CD47, results in decreased cGMP levels, a downstream 
product of the NO activated -dilatory pathway. In this thesis we present data demonstrating for 
the first time that levels of TSP1 that fall within the normal physiologic range observed in blood, 
inhibit the NO mediated-pathway upstream of cGMP production, at the level of eNOS. We 
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further show in isolated aortas of wild type mice that addition of TSP1 at these normal 
physiologic levels (2.2 nM) shifts the dose-response curve of endothelial dependent relaxation 
upwards (Fig.7A). Vessels treated with TSP1 thus require a higher dose of ACh to obtain the 
same level of endothelium-dependent relaxation as observed in untreated vessels. As proof of 
principle we further demonstrated that addition of TSP1 had no effect on vessels isolated from 
CD47 null mice (Fig.8C). In addition infusion of low levels of TSP1 (2.2nM) into anesthetized 
TSP1 null mice as well as wildtype mice significantly raised their blood pressure indicating that 
TSP1 functions as vasopressor by dampering NO production (Fig.10 ). 
5.3 TPS1 AS NEGATIVE REGULATOR OF ENOS 
The regulation of eNOS is complex and full activity of the enzyme is dependent on its 
phosphorylation at specific residues, interaction with other proteins, as well as cellular calcium 
and oxygen levels. In vitro studies in systemic human endothelial cells demonstrated that the 
interaction of TSP1 with CD47 inhibits eNOS at various levels. Treatment of endothelial cells 
with TSP1 resulted in drastically decreased enzyme phosphorylation at serine 1177, a well 
established phosphorylation site indicative of enzyme activity, in response to ACh (Fig.6B). We 
additionally checked for phosphorylation at threonine 495, a site known to mediate inhibition of 
eNOS. In our hands we did not observe any change in phosphorylation at that site (data not 
shown). Others have found similar difficulties observing phosphorylation events at that threonine 
to known inhibitors of eNOS (PM Bauer, Bill Sessa).  
The interaction of a variety of proteins with eNOS influences its enzymatic activity as 
well. Activation of eNOS has been shown to coincide with dissociation of cav-1, increased 
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association with HSP90, and increased association with the calcium-dependent protein 
calmodulin. Pretreatment of endothelial cells with TSP1 resulted in an abrogation of the normal 
increase in HSP90/eNOS association in response to ACh.  We were unable to detect changes in 
cav-1 association with eNOS after TSP1 exposure (data not shown). The regulation of eNOS is 
dynamic and our results do not exclude the possibility that changes in the interaction of eNOS 
with cav-1 could change over time or under different stimulatory conditions.   
Interestingly, we observed that addition of TSP1 led to modulation of calcium flux in 
response to ACh (Fig. 5) in both cultured endothelial cells as well as the isolated mouse aorta.  
We initially assumed that this modulation of calcium flux would also translate to visible changes 
in the interaction of eNOS with the calcium-dependent protein calmodulin. However, we did not 
observe this under our conditions (data not shown). Further exploration of calcium’s exact role 
and mechanism in the context of TSP1 will be interesting for future studies. 
 Independent of the exact dynamic changes occurring on eNOS itself due to exposure to 
TSP1, the overall outcome showed a significant decrease in enzyme activity. Ultimately 
decreased eNOS activity leads to decreased production of NO, decreased cGMP production (as 
previously shown by our group) and an overall increased vascular tone. Summarizing, we thus 
demonstrated for the first time that TSP1 inhibits eNOS activity and that the mechanism of 
inhibition occurs at multiple levels. 
5.4 THE ROLE OF TSP1 IN PULMONARY HYPERTENSION 
Analysis of lung tissues from patients with PH demonstrated a significant increase in TSP1 
protein expression and led to our exploration of TSP1’s role in this disease using the model of 
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hypoxia-induced pulmonary hypertension. We observed that TSP1 null mice exposed to chronic 
hypoxia were significantly protected from the development of PH. In comparison to WT mice 
with hypoxia-induced PH, TSP1 null mice displayed lower right ventricular systolic pressures, 
lower right ventricular hypertrophy as well as less arteriolar muscularization in the lung. We also 
observed their ability to thrive under hypoxic conditions by not losing body weight as compared 
to the WT mice (Supplemental Figures under Appendix A). 
Further experiments focused on changes in eNOS regulation and revealed that cav-1 
expression is increased in the hypoxic TSP1 null compared to the hypoxic WT mice. While both 
hypoxic groups experienced the same level of eNOS uncoupling and thus increased ROS 
production, this harmful effect is dampened by the overall inhibitory effect that cav-1 has on 
eNOS (Fig ). Additionally nitrotyrosine staining of the pulmonary vasculature, characteristic of 
ROS production, was decreased in the hypoxic TSP1 null mice compared to the strong staining 
of the hypoxic WT mice. 
One of the most commonly prescribed drugs to treat PH is sildenafil, a PDE5 inhibitor. 
By inhibiting enzymatic activity of PDE5, the breakdown of cGMP is slowed, increasing the 
overall cGMP levels and thus leading to increased vasodilation. Though widely prescribed, it has 
also been shown that many patients seem not to respond to PDE 5 inhibitors. This dissertation 
has demonstrated that 1) TSP1 inhibits eNOS directly and 2) that TSP1 levels are significantly 
increased in PH patients. It might thus be possible that drugs targeting this pathway downstream 
of eNOS will have less efficacy due to upstream inhibition of eNOS as well as inhibition of sGC 
and PKG. 
Another group of drugs used to treat PH targets vasoconstrictors. Increased levels of 
vasoconstrictors have been observed in patients with PH and a variety of antagonists have been 
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developed. This dissertation demonstrates that TSP1 functions as pressor and thus can contribute 
to the overall increased vasoconstictive vascular tone in PH. 
The development of drugs that target CD47 directly or TSP1 might therefore be able to 
treat two problems by developing one drug that can block the TSP1/CD47 interaction. It would 
lower the vasoconstrictive effect of TSP1 and would remove the inhibition of eNOS.  
 
 
Figure 18.  Schematic describing the proposed role  of TSP1 in pulmonary hypertension.   
TSP1 is proposed to play a dual role in the development of pulmonary hypertension.  Initially, by limiting eNOS 
activation and downstream signaling, TSP1 may lead to loss of bioavailable eNOS and endothelial dysfunction.  As 
the disease progresses TSP1 promotes conditions leading to increased superoxide production from uncoupled eNOS 
including increased Akt activation and suppression of caveolin-1 expression. 
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5.5 SUMMARY AND FUTURE DIRECTIONS 
The studies herein illustrate two novel findings: first, addition of TSP1 to cells and isolated 
vessels and animals, inhibits the classical NO-mediated vasodilatory pathway by directly 
inhibiting eNOS activity. This effect of TSP1 is upstream of its previously shown inhibition at 
the cGMP and PKG level. Secondly, in the disease setting of pulmonary hypertension, TSP1 
levels of patients are significantly elevated and, in an animal model, aggravate the progression of 
the disease. We further observed that the effect of TSP1 is associated with increased production 
of reactive oxygen species. Taken together, these studies demonstrate that TSP1 acts as novel 
negative regulator of the NO dilatory pathway and targets it at multiple levels. We further 
observed that TSP1 is intimately involved in vascular disease. In summary, as this new role of 
TSP1 in the vascular environment emerges, it creates new targets for the development of 
therapeutic drugs. 
The main goal of this study was to shed light onto the role of TSP1 in a physiologic 
setting by focusing on the organism as a whole. Future studies therefore can further decipher the 
exact mechanisms involved that are regulated by TSP1 as demonstrated by us here. As such the 
modulation of calcium flux in response to TSP1 could lead into studies of G-protein coupled 
receptor signaling occurring possibly in parallel to the regulation of eNOS. Another question to 
be explored would be the potentially limiting effect of calcium flux on the ability of eNOS, a 
calcium dependent enzyme, to fully function. The regulation of eNOS is very complex, 
depending not only on certain phosphorylation sites but also several cofactors and interacting 
proteins. It would be beneficial to understand the temporal order of events leading to decreased 
eNOS activity to allow for more specific drug targets. 
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While this study focused on the role of TSP1 in pulmonary hypertension, it would be 
beneficial to extend this research to other vascular diseases of endothelial dysfunction, like 
atherosclerosis or diabetes.  For the studies discussed here we focused on the endothelium. 
However, another unknown is the role of TSP1 on smooth muscle. In atherosclerosis the smooth 
muscle layer extends into the lumen of the vessel proliferating past the endothelium and thus is 
in direct contact with TSP1. All of these studies will help us to better understand disease and 
hopefully allow us to treat and ultimately prevent it. 
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APPENDIX A:  SUPPLEMNTAL FIGURES 
 
Figure 19. Myogenic response of CD47 null to a variety of vasoconstrictors 
A variety of different vaso-constrictors was added sequentially to four aortic rings of one CD47 null mouse. The 
maximum response to PE was set to be 100 % and compared the other agonists. Interestingly these null vessels only 
responded to PE and thromboxane. However, even the PE response is significantly blunted when compared to a WT 
mouse. 
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 Figure 20. TSP1 null mice thrive under hypoxia 
After 21 days of exposure to hypoxia, TSP1 null mice did not lose any significant amount of body weight compared 
to hypoxic WT mice. Taking body weight as an indicator of overall well being, the TSP1 null mice appeared to 
thrive compared to WT mice (n=8 per group, * = p<0.05significance) 
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APPENDIX B:  ZINC-INDUCED ACTIVATION OF PKC-EPSILON MODULATES
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ABSTRACT 
PKCepsilon (PKCε) is a novel calcium independent and zinc sensitive kinase that has been 
implicated in vascular contraction. Our lab has previously shown that acute hypoxic exposure 
induces nitric oxide (NO)-mediated increases in intracellular labile zinc  in pulmonary 
endothelium which contribute to contraction of small intracinar arteries of the isolated perfused 
lung (IPL) 301.We now show that inhibition of PKC by Ro-31-8220, or infection with a herpes 
virus expressing dominant negative PKCε, significantly attenuated the hypoxia induced 
contraction of isolated pulmonary endothelial cells, and that pharmacologic inhibition of PKCε 
significantly decreased hypoxic pulmonary vasoconstriction (HPV) in the IPL. Cell fractionation 
andWestern blot analysis revealed that either hypoxia, or exogenously applied zinc, induced 
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translocation of PKCε from the cytosolic to the membrane fraction in isolated pulmonary 
vascular endothelial cells that were accompanied by NO-dependent increases in PKCε activity. 
Furthermore, zinc-induced phosphorylation of the contractile regulatory protein, myosin light 
chain (MLC) was shown to be PKC -dependent. Collectively, these data suggest that PKCε 
serves one effector molecule mediating zinc/hypoxia-induced constriction in the pulmonary 
microvasculature.  
 
INTRODUCTION 
Hypoxic pulmonary vasoconstriction (HPV) is a complex, multifactorial phenomenon resulting 
in the shunting of blood from areas of poor gas exchange to better ventilated regions of the lung 
302. As such, HPV is an important physiologic regulator of ventilation:perfusion matching in the 
lung; though sustained HPV is associated with vascular remodeling ultimately leading to 
pulmonary hypertension. While the precise mechanism underlying HPV remains unclear, it is 
thought that intrinsic properties of pulmonary vascular smooth muscle (oxygen sensing and 
coordination of ionic conductances) that are modulated by communication with endothelium 
(biosynthesis of vasoactive substances including NO) account for hypoxic mediated 
vasoconstriction of pulmonary arteries 303.  Our previous studies showed that zinc thiolate 
signaling is a component of acute hypoxia mediated NO biosynthesis and that this pathway 
contributes to hypoxic induced vasoconstriction within the pulmonary microcirculation 301.  
The mechanism by which zinc can induce vasoconstriction in the pulmonary vasculature is not 
known. However, zinc-associated proteins account for a large part of mammalian proteome and 
many of these candidate targets are components of signaling and effector pathways in cellular 
contraction. Intracellular zinc concentrations have been shown to influence protein kinase C 
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(PKC) activity and processing 304-306; and PKC is an important signaling molecule mediating 
contractile responses in both the systemic and pulmonary circulations 307-309..  While the roles of 
individual isoforms of PKC in the control of pulmonary vascular reactivity have not been clearly 
defined, PKCε has been implicated in contraction of the systemic vasculature 310 and is a critical 
mediator of ischemic preconditioning in the myocardium 311-312. Pertinent to our studies of 
pulmonary vascular reactivity, wide-body deletion of PKCε was shown to blunt murine HPV 
leaving ANGII and KCl responses preserved 313. We hypothesized that PKCε, a zinc sensitive 
signaling molecule in HPV transduces hypoxia mediated changes in zinc homeostasis to induce 
constriction of the pulmonary microvasculature. 
 
METHODS 
Chemicals and Materials: All reagents were purchased from Sigma-Aldrich 
(www.sigmaaldrich.com) unless otherwise noted. The GFP-dominant negative PKCε herpes 
simplex virus was provided by Joseph Glorioso 314. 
Cell Culture: Cells were grown at 37°C with 5% CO2.  Details regarding the harvest and culture 
of sheep pulmonary artery endothelial cells (SPAEC) are described elsewhere 315Rat pulmonary 
microvascular endothelial cells (RPMEC) and rat aortic endothelial cells (RAEC) were 
purchased from VEC Technologies (VEC Technologies Inc, Resselaer, NY) and grown in 
complete MCDB-131 (Lonza). Rat pulmonary artery endothelial cells (RPAEC) were grown in 
Dulbecco Modified Media (Fisher Scientific) with 10% fetal bovine serum, 2 mM glutamine, 
100 U/ml penicillin/streptomycin.  
 For the zinc treatments described in subsequent sections, cells were incubated in 10 µM 
zinc in combination with the zinc ionophore, pyrithione (5 μM). Chelation of intracellular zinc 
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was achieved by preincubation of cells with N,N,N’,N’-Tetrakis-(2-pyridylmethyl)-
Ethylenediamine (TPEN,10 µM) for 30 m prior to any additional treatment. 
Animals: Sprague Dawley rats were purchased from the Jackson Laboratories (Bar Harbor, ME) 
and housed in a pathogen free environment with ad libitum access to filtered water and standard 
rat chow. All studies were performed using protocols approved by the Institutional Animal Care 
and Use Committee (IACUC) at the University of Pittsburgh and following the guidelines of the 
American Physiological Society. 
Cell Membrane Fractionation: Cells were lysed (100 mM Tris·HCl, pH 7.4, 1%, v/v Nonidet P-
40, 10 mM NaF, 1 mM vanadate, 10 μg/ml of aprotinin, 10 μg/ml of leupeptin) and centrifuged 
for 10 m at 14000 rpm. The supernatant was further centrifuged at 43,000 x g for 30 m 316. The 
resulting supernatant was then used as cytoplasmic fraction and the resuspended pellet as 
membrane fraction. Protein concentrations were determined using Lowry’s assay to allow for 
equal gel loading and at least 15 µg total protein per fractions were used for Western blot 
analysis. 
PKCε Immunoprecipitation and Enzyme Activity Assay:  Cells were washed twice with PBS, 
and lysed in modified RIPA buffer (100 mM Tris·HCl, pH 7.4, 1%, v/v, Nonidet-P40 10 mM 
NaF, 1 mM vanadate, 10 μg/ml of aprotinin, 10 μg/ml of leupeptin). Insoluble material was 
removed by centrifugation and protein concentrations determined using the Bio-Rad DC protein 
assay. Equal amounts of protein were precleared with protein A-Sepharose and then incubated 
with monoclonal PKCε antibody for 2 h at 4 °C. The immune complexes were isolated with 
Protein A-Sepharose, washed and eluted. Equal amounts of immunocomplex were then subjected 
to PKCε kinase assay, as described previously 317 In brief, the assay was carried out by 
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coincubating 20 μl of immunoprecipitated PKCε with 50 μM ATP, 5 μg of phosphatidylserine, 
40 μM PKCε substrate peptide (a preferred substrate of PKCε, Upstate Biotechnology, Lake 
Placid, NY), 0.2 μl of [32P]ATP (Perkin Elmer Life and Analytical Sciences, Boston, MA) in a 
final volume of 50 μl. The reaction was allowed to proceed at 30°C for 10 min. An aliquot of the 
reaction mixture was then spotted on p81 paper, washed in 5% acetic acid, and counted in the 
scintillation counter. 
 Western Blot: Equal amounts of cytoplasmic and membrane fractions were separated by SDS–
PAGE and transferred to nitrocellulose membranes. Membranes were blocked in TBST (Tris 
buffered saline, 0.1% Tween 20), 5% non-fat dry milk for 30 min, followed by incubation in 
primary antibody over night (mouse PKCε antibody, Santa Cruz; rabbit β-actin, BD Cell 
Signaling; rabbit phosphoMLC(18/19) Cell Signaling). Membranes were washed in TBST prior 
to incubation for 1 h with horseradish peroxidase-conjugated secondary antibodies. Membranes 
were washed and developed using enhanced chemiluminescence substrate (Pierce 
Biotechnology, Rockford, IL).  The protein level of PKCε in each sample was normalized to the 
level of β-actin.  
Isolated Perfuse Rat Lung: Male Sprague-Dawley rats (300-350g) were anesthetized i.p. with 
0.8 ml pentobarbital (Nembutal, sodium solution, 50 mg/ ml). Following a tracheotomy rat lungs 
were ventilated (model 683, Harvard Apparatus, Holliston, MA) with humidified normoxic (20% 
O2, 5% CO2, 75% N2) or humidified hypoxic (1.5% O2, 5% CO2, 75% N2) air  at 48 
breaths/min, 2 cm positive end-expiratory pressure (PEEP) and with tidal volumes between 2.5-3 
ml based on body weight. A thoracotomy was performed to expose heart and lungs, and 100 µl 
heparin (Abraxis Pharmaceutical Products, Schaumburg, IL) was injected in the right ventricle. 
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After cannulating the pulmonary artery and left atrium, flow was increased to 12 ml/min. Initial 
blood containing perfusate was discarded, and replaced with recirculating clean perfusate. The 
perfusion buffer was warmed Krebs-Henseleit buffer supplemented with 4% Ficoll, 3.1 μM 
meclofenamate and 2.8 mM CaCl2 (pH 7.38). The pH was continuously monitored and adjusted 
by bubbling with 5% CO2. Pressure was continuously monitored during pulmonary perfusion and 
recorded at constant flow (PowerLab, ADInstruments, Inc., Colorado Springs, CO). The 
preparation was allowed to equilibrate for 15 min followed by priming with 150 ng angiotensin 
II via bolus injection. The IPL was then exposed to three successive 5 min episodes of alveolar 
hypoxia separated by 10 min recovery. Ro-31-8220 was added to the perfusate (final 
concentration 2 μM) and after further perfusion with inhibitor for 10 min, the IPL was exposed 
to 2 successive 5 min hypoxic periods.  
Cell contraction assay:  RPMEC and SPAEC were seeded on 35 mm collagen coated glass 
bottom dishes (MatTek Corporation, Ashland, MA) and imaged in a closed, thermo-controlled 
(37ºC) stage insert (Tokai-Hit, Tokyo, Japan). Images were obtained using a Nikon TE2000E 
inverted microscope equipped with a 40X oil immersion objective (Nikon, CFI PlanFluor, NA 
1.3) and Q-Imaging Retiga EXI camera (Burnaby, BC, Canada). MetaMetamorph (Molecular 
Devices, Downingtown, PA) was used to collect and analyze data and to drive the microscope. 
After collection of baseline images, cells were exposed to an anoxic gas mixture (5% CO2, 95% 
N2) that was shown to acutely reduce oxygen tension to13 ± 2 mmHg, as measured using a 
Clarke electrode. Contractile events due to changes in oxygen tension were determined by 
changes in cell surface area 301. PKCε was inhibited pharmacologically in RPMECs by addition 
of Ro-31-8220 (1 μM) to the culture media 30 min prior to hypoxic stimulation.  SPAECs were 
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infected with dominant negative PKCε using a replication deficient herpes simplex viral vector 
314 24 h prior to imaging.  
Statistical Analysis:  Results are given as mean ±SD. Data were analyzed using a one-way 
analysis of variance for multiple comparisons with post-hoc Tukey tests for pairwise 
comparisons. Significance was set at P < 0.05. 
 
RESULTS 
 
Inhibition of PKCε attenuates hypoxia-induced contraction of isolated pulmonary 
endothelial cells. We previously reported that: a) S-nitrosation of zinc sulfur clusters is an 
important component of NO signaling; and b) the heavy metal-binding protein, metallothionein 
(MT) is a critical link between NO and intracellular zinc homeostasis 318-319.  We further showed 
that zinc thiolate signaling is a component of the effects of acute hypoxia mediated NO 
biosynthesis and that this pathway contributes to constriction in pulmonary endothelium 301. 
Likely participants in such signaling include PKC isoforms that are known to be tightly regulated 
by zinc and participate in HPV (i.e. PKCε). We examined a potential role of PKCε in mediating 
hypoxia-dependent contractile behavior at the level of the single cell using high resolution 
differential interference contract (DIC) imaging of changes in cell surface area in live rat 
pulmonary microvascular endothelial cells (RPMEC) and sheep pulmonary artery endothelial 
cells (SPAEC). A role for PKCε in mediating hypoxia-induced endothelial cell contraction was 
initially investigated using the PKC inhibitor Ro-31-8220 which has been shown to inhibit PKCε 
with an IC50 of 0.024 µM. Cellular contraction was assessed using measurement of cell surface 
area 301. Figure 1A shows a representative field of cells at baseline (A, D), during hypoxia (at 30 
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min, B, E) and following the recovery period (30 min, C, F). The hypoxia induced decreases in 
surface area were significantly attenuated in the presence of the PKCε inhibitor, Ro 31-8220 
(from 16 ± 7% to 4.5 ± 6% with Ro-31-8220, P < 0.005, Figure 1B). Due to concerns regarding 
the use of pharmacological inhibitors to individually target specific isoforms of PKC, we also 
adopted a dominant negative approach to study the role of PKCε in modulating hypoxia-induced 
endothelial cell contraction. SPAEC were infected with a GFP-tagged herpes simplex virus 
encoding dominant negative PKCε (Figure 2A) 24 hrs prior to hypoxic exposure. The infection 
efficiency was extremely low in the RPMEC, and thus, for these studies, they were replaced with 
SPAEC which have been shown to: 1) increase NO production when exposed to acute hypoxia 
301; 2) increase intracellular labile zinc in response to NO 315, 319; and 3) contract in response to 
hypoxic exposure (Figure 2).  We compared hypoxia-induced contractile responses between cells 
expressing the dominant negative PKCε construct (green) with uninfected cells within the same 
experiment. The 17.0 ± 5.5% decrease in area in the uninfected cells was significantly greater 
than the contraction observed in cells expressing PKCεDN (0.2 ± 7.0%, P = 0.012, Figure 2B). 
These data suggest that PKCε serves as one effector molecule mediating hypoxia-induced 
constriction in the pulmonary microvasculature. 
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Figure 21.PKC inhibition attenuates hypoxia induced contraction in rat pulmonary microvascular 
endothelial cells (RPMEC).  
The images show the same representative field of cells at baseline (A, D), during hypoxia (at 30 min, B, E) and 
following the recovery period (30 min, C, F). The hypoxia-induced contraction shown in panels A-C was 
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significantly attenuated in the presence of the PKCε inhibitor, Ro-31-8220 (1 µM, panels D-F). The mean data for 6 
separate experiments (with 3-5 cells per experiment) is shown in the bar chart (P < 0.05).  
 
Figure 22. Dominant negative PKCε attenuates hypoxia induced contraction of sheep pulmonary 
artery endothelial cells (SPAEC)  
The images show a representative field of cells at baseline (A), during hypoxia (at 30 min, B) and following the 
normoxic recovery period (30 min, C). The contractile responses of cells expressing the GFP-tagged PKCεDN 
construct (green) were compared to cells that were not infected.  In the example shown, the uninfected cell (cell 1) 
shows 10% decrease in area as compared to cells expressing PKCεDN (cells 2 and 3). The mean data for 4 separate 
experiments (with 2-6 cells per group per experiment) are shown in the bar chart (P < 0.05).  
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Pharmacologic inhibition of PKC attenuates hypoxic pulmonary vasoconstriction (HPV) in 
the isolated perfused rat lung. We have reported previously that hypoxic vasoconstriction is 
blunted in IPL of MT–/– mice and in wild-type mice, or rats, treated with the zinc chelator, 
N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN), revealing a role for zinc in 
modulating  HPV 301. The data obtained in isolated cells (Figures 1 and 2) suggest that the zinc-
sensitive kinase, PKCε, also contributes to hypoxia induced contraction of pulmonary 
endothelium. Before further delineation of this component of the NO-zinc signaling pathway, we 
confirmed a role for PKC in mediating hypoxia induced contraction at the level of the intact 
tissue. Figure 3A shows representative pulmonary artery pressure tracings from isolated and 
ventilated rat lungs which were perfused in situ using constant flow. After a 15 min equilibration 
period and a stimulatory bolus injection of 150 ng angiotensin II, the lungs were exposed to two 
rounds of hypoxic ventilation (5% oxygen). Ro-31-8220 (2 μM) was added to the perfusate 
during normoxia. After a 10 min equilibration period in the presence of the inhibitor, the IPL was 
exposed to 2 further periods of hypoxia. Inhibition of PKCε with Ro-31-8220 blunted hypoxia-
induced increases in pulmonary perfusion pressure by 56.9 ± 20.0 % (Figure 3B, P = 0.018). 
While decreased HPV has also been observed in PKCε null mice 313, this response was attributed 
to adaptive effects of gene knockout and increased expression of Kv3.1 channel expression in 
pulmonary vascular smooth muscle, rather than a direct result of specific PKCε deletion. Our 
present data obtained using Ro-31-8220, are in agreement with previous reports showing that 
pharmacologic PKC inhibition (i.e phloretin) in rats, dogs, and rabbits blunts HPV 308, 320.  One 
advantage of using pharmacologic inhibitors to reveal a role for PKCε in mediating pulmonary 
vascular contraction is that such acute exposures (< 1 hour) would not be expected to alter 
expression patterns of hypoxia-sensitive ion channels.       
 105 
 Figure 23. Pharmacological inhibition of PKC blunts hypoxic pulmonary vasoconstriction in the 
isolated perfused lung (IPL) 
Representative pulmonary artery pressure tracings from the same rat showing the HPV response to hypoxia in the 
absence (A), and presence of Ro-31-8220 (B). PKC inhibition significantly blunted HPV (P <0.01, n=6). 
 
Acute hypoxia induces zinc and nitric oxide (NO)-dependent increases in PKCε enzyme 
activity in pulmonary endothelium.  We have previously shown that acute hypoxia induces an 
NO-mediated increase in FluoZin-3 detectable zinc in isolated pulmonary endothelial cells as 
well as in the isolated perfused lung 301.  We now hypothesize that hypoxia-induced zinc release 
can modulate contractile events in pulmonary endothelium via modulation of PKCε activity. 
PMA has been shown to activate PKC enzyme activity and cause physical translocation of the 
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enzyme from the cytosol to the membrane fraction in cells 312, 321.  We used cell fractionation via 
ultracentrifugation followed by Western blot analysis to confirm that PMA induced PKCε 
protein translocation between the membrane and cytosolic fractions in primary pulmonary artery 
endothelial cells isolated from rat (RPAEC, Figure 4A). When RPAEC were exposed to acute 
hypoxia (1.5% for 15, 30, 60 min) we observed a time-dependent decrease in PKCε protein 
levels in the cytosolic fraction (P<0.05, Figure 4B) and a corresponding increase in the 
appearance of the protein in the membrane fraction (P<0.05, Figure 4C). These hypoxia induced 
effects were reversed by addition of the zinc specific chelator TPEN (10 μM) (Figure 4B, 
P<0.001). Similar changes in PKCε localization were achieved by addition of exogenous zinc to 
the media during normoxia (Figure 4C,D, P < 0.05). Furthermore, exogenous zinc (10 μM) was 
shown to be associated with increases (P < 0.05) in PKCε enzyme activity which were reversed 
by addition of TPEN (10 μM) (Figure 5).  Exposure of RPAEC to acute hypoxia was also 
associated with time-dependent increases in PKCε enzyme activity (Figure 5) that were reversed 
by the addition of the NOS inhibitor, L-Name (1mM, P < 0.05), or the zinc specific chelator 
TPEN (10 µM, P < 0.001). Collectively, these data suggest that the effects of hypoxic exposure 
on PKCε enzyme function in isolated pulmonary endothelial cells are regulated by NO-mediated 
changes in zinc homeostasis.  
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Figure 24. PKCε translocates from the cytosol to the membrane fraction in response to PMA, 
hypoxia, and zinc 
RPAEC were incubated for 10 min with PMAand membrane and cytosolic fractions separated by ultracentrifugation 
followed by Western blot analysis against PKCε. Quantification of the intensity of bands showed a loss of PKCε 
protein in the cytoplasm and an increase in the membrane fraction following PMA treatment (A). Pulmonary 
endothelial cells were exposed to hypoxia (60 min) followed by fractionation and Western blot analysis against 
PKCε. Quantification of the intensity of bands showed a significant loss of PKCε protein in the cytoplasm (B), and 
increased accumulation in the membrane fraction in response to hypoxia (C). These changes were reversed by the 
addition of 10 μM TPEN. Treatment with exogenous zinc also resulted in a significant loss of PKCε protein in the 
cytoplasm and accumulation in the membrane fraction (D) which was reversed by TPEN (10 µM). For all blots 
intensity values were normalized by dividing each lane to the β-actin intensity value. Each Western is a 
representative blot and each graph is the result of at least 3 independent experiments (* P < 0.05, ** P < 0.001). 
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Exogenous zinc induces phosphorylation of the myosin regulatory light chain (MLC) at 
Thr18/Ser19. Force generation requires extensive remodeling of the actin cytoskeleton. As is the 
case in smooth muscle cells, changes in contractile force are accomplished via the regulation of 
the level of phosphorylation of the regulatory myosin light chain (MLC) 322. We used 
immunoblotting to show that exogenous zinc (10 μM) can itself induce Thr18/Ser19 
phosphorylation in isolated pulmonary endothelial cells (Figure 6). The zinc-induced 
phosphorylation of MLC was decreased almost to baseline by either zinc chelation (TPEN, 25 
μM) or by PKC inhibition with Ro-31-8220. TPEN and Ro-31-8220 in combination reduced the 
phosphorylation event below baseline levels. In combination, these data suggest that PKC is one 
of the key signaling molecules transducing the effects of zinc on cellular contraction in 
pulmonary endothelium. 
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B. HYPOXIA 
 
 
 
 
 
 
 
 
Figure 25. Hypoxia increases PKCε activity in rat pulmonary artery endothelial cells (RPAECs) in a 
NO and zinc dependent manner 
Zinc-induced increases in PKCε activity (A) were reversed by TPEN (10 µM). The graph is the result of 3 
independent experiments (p<0.05). Enzyme activity observed in normoxic cells was increased significantly by 
exposure to acute hypoxia (B). The changes were reversed by the competitive NOS inhibitor L-Name (1 mM) or the 
zinc-specific chelator, TPEN (10 µM). The graph is the result of 3 independent experiments (p<0.05). 
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Figure 26. Exogenous zinc (10 μM) increases Thr18/Ser19 phosphorylation in rat pulmonary artery 
endothelial cells (RPAECs).  
The zinc-induced phosphorylation of MLC was decreased almost to baseline by either zinc chelation (TPEN, 25 
μM) or by PKC inhibition with Ro-31-8220. TPEN and Ro-31-8220 in combination reduced the phosphorylation 
event below baseline levels. 
 
Discussion 
We demonstrated that: 1) PKCε inhibition blunted hypoxia-induced contraction of isolated 
pulmonary endothelial cells, and attenuated HPV in the isolated perfused lung; 2) hypoxic 
exposure induced translocation of PKCε from the cytosolic to the membrane fraction, 
accompanied by NO- and zinc-dependent increases in PKCε activity, in primary cultures of 
pulmonary endothelial cells; and 3) under normoxic conditions, exogenous zinc caused increases 
in PKCε activity and resulted in PKC-dependent phosphorylation of myosin light chain, an 
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important signaling element mediating contractile activity in a number of cell types. Collectively, 
these data implicate PKCε as one target molecule regulating the effects of nitric oxide released 
zinc on contraction of pulmonary endothelium.   
PKC activators, including mimicks of the natural ligand diacyglycerol (i.e. phorbol myristae 
acetate (PMA)) stimulate contraction, and potentiate HPV 308; whereas PKC inhibitors decrease 
HPV308, 320, 323.  However, investigating the involvement of PKCε in HPV is complicated by the 
lack of specificity of the pharmacological inhibitors and activators of individual PKC isoforms. 
Ro-31-8220 has an IC50 of 0.024 µM for PKCε, however at high concentrations it can also 
inhibit PKCα, PKCβII and PKCγ . The difficulties in using such inhibitors are further 
demonstrated by observations that Ro-31-8220 has been shown to be able to activate c-Jun 
expression and inhibit mitogen-activated protein kinase (MAP kinase) phosphatase-1 expression 
324-325 . While it is possible that multiple isoforms of PKC contribute to the contraction of the 
pulmonary vasculature, and we cannot eliminate the possibility that these play a role in 
modulating the response to hypoxia observed in the IPL, the observation that the dominant 
negative approach to specifically inhibit PKCε also significantly attenuated the hypoxia-induced 
contraction of isolated cells confirmed the importance of the PKCε isoform in mediating 
contraction of pulmonary endothelium. 
The specificity of the proposed PKCε pathway in mediating hypoxia induced contraction in the 
pulmonary vasculature is not known. We have previously shown that both hypoxia-induced 
changes in labile zinc and hypoxia-induced endothelial cell contraction 301 were unique to cells 
derived from lung in that aortic endothelium did not exhibit these responses to low PO2. 
However, we do not anticipate that the tissue specificity of HPV is conferred by activation of 
PKCε in that PKC has been shown to be an important signaling molecule mediating contractile 
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responses in both the systemic and pulmonary circulation 307, 323. The importance of PKC signal 
transduction pathways in the modulation of myogenic reactivity is well established 309. Purported 
mechanisms include depolarization-induced voltage gated calcium channel activation, Ca2+ 
sensitization, and/or myosin light chain phosphatase inhibition326-328.  
Intracellular zinc concentrations are known to influence PKC activity and processing 304-306. We 
recently observed that zinc contributed to tBH-induced necrosis, in part, via a PKC-dependent 
pathway, providing one potential link between zinc and PKC in pulmonary endothelium329-330. 
The diacylglycerol (DAG)-binding sites of PKC have been mapped to two pairs of Zn fingers in 
the regulatory domain. Each finger contains six cysteines that fold to form a structure that 
coordinates 2 Zn atoms 331-332. While oxidative stress is thought to activate PKC by modifying 
zinc thiolate clusters of the regulatory domain of the NH2 terminus, relieving autoinhibition and 
facilitating cofactor independent PKC activation 331, it has been suggested that changes in 
intracellular zinc affect PKC activity by targeting the enzyme’s C1 domain which contains 
cysteine rich finger like motifs that bind zinc 304.  
NO donors have been shown to induce activation, translocation, and nitration of PKCε in cardiac 
myocytes 330. In fact, both eNOS and iNOS proteins are associated with PKCε in the heart 312, 
though data obtained in PKCe -/- mice suggest a  role for PKCε in the regulation of eNOS 
expression during chronic hypoxic exposure rather than in the direct regulation of enzymatic 
activity 313.  The TPEN sensitivity of both PKC activation and MLC phosphorylation suggest 
that zinc is required for the hypoxia-induced regulation of pulmonary endothelial cell 
contraction.  
It has been reported that increased production of reactive oxygen species (ROS) during hypoxia 
contributes to  HPV 333-334; and there is accumulating evidence that increases in ROS, 
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particularly superoxide, can activate PKCε in pulmonary smooth muscle 335-336. In our hands, the 
hypoxia-induced changes we observed in PKCε activity were both L-NAME and TPEN sensitive 
arguing for a role for NO-induced changes in labile zinc in mediating enzyme function. Indeed, 
our data show that zinc itself can induce contraction (data not shown), PKCε activation as well 
as PKCε-dependent phosphorylation of MLC in pulmonary artery endothelial cells.  
Endothelial cells contain all the molecular machinery required to generate contractile force via 
the actomyosin motor. Endothelial cell contraction is initiated by phosphorylation of the 20 kDa 
regulatory myosin light chain (MLC) at ser19/thr18 337. MLC phosphorylation is dependent upon 
a balance between the activities of calcium/calmodulin dependent MLC kinase (MLCK) and 
myosin light chain phosphatase (MLCP). Our data shows that the zinc induced phosphorylation 
event is significantly attenuated by PKC inhibition. One potential pathway by which PKC could 
indirectly cause increases in MLC20 phosphorylation is via inhibition of MLCP 328, 338. 
Regulation of MLCP has been shown to involve the PKC substrate, CPI-17; a potent inhibitor of 
the phosphatase 339-341. The PKC-CPI-17 pathway has been reported to be involved in the 
regulation of MLC phosphorylation, reorganization of microfilaments and focal adhesions, and 
histamine-induced barrier dysfunction in pulmonary endothelium 316.  
Summary. Our data suggest a role for PKC in mediating the downstream effects of hypoxia-
induced changes in intracellular zinc homeostasis to produce contraction of pulmonary 
endothelium. While data obtained using dominant negative approaches directly implicate the 
involvement of PKCε, we cannot eliminate the possibility that other isoforms of PKC also 
contribute to HPV and/or the generation of contractile force in isolated pulmonary endothelial 
cells. 
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